



Cite this: DOI: 10.1039/d5ma01412c

Multi-functional biomedical applications of nanoencapsulated herbal essential oils: polymer-based encapsulation strategies and key biological properties

Hamid Rajabi,^a Utcharaporn Kamsrijai,^b Narudol Teerapattarakon,^b Sulukkana Noiprasert,^c Huang Zhaoxian,^d Marc Pignitter^e and Saroat Rawdkuen^{id}*^{ac}

Herbal essential oils (HEOs) possess broad-spectrum biological activity but their biomedical translation is limited by volatility, poor aqueous solubility, chemical instability, and compositional variability. This review critically synthesizes recent advances in polymer-based nanoencapsulation as a strategy to modulate the physicochemical and biological behavior of HEOs. Delivery platforms including polymeric nanoparticles, nanoemulsions, hydrogels/nanogels, electrospun nanofibers, and hybrid assemblies are analyzed with emphasis on structure–function relationships. Particular attention is given to how polymer selection governs mucoadhesion, degradability, release kinetics, cellular interaction, and compatibility with hydrophobic phytoconstituents. Across diverse biomedical contexts, encapsulation consistently alters exposure profiles and improves therapeutic indices relative to free oils, enhancing antimicrobial and antibiofilm performance, modulating inflammatory and oxidative pathways, promoting wound repair, and increasing selective cytotoxicity in cancer models. These effects are linked to improved physicochemical stabilization, controlled release behavior, and architecture-dependent cellular uptake mechanisms. Despite substantial progress, translational barriers remain, including limited long-term *in vivo* safety data, challenges in chemotype standardization, batch-to-batch variability, and constraints in GMP-compliant scale-up. Future development will depend on integrating rigorous quality control, scalable manufacturing technologies, and data-driven formulation design to establish clinically and industrially viable HEO-based nanotherapeutic systems.

Received 4th December 2025,
Accepted 16th May 2026

DOI: 10.1039/d5ma01412c

rsc.li/materials-advances

1. Introduction

Over recent decades, natural products have re-emerged as structurally diverse reservoirs of bioactive compounds that inform modern therapeutic and formulation strategies.¹ Rather than replacing synthetic drugs, plant-derived molecules increasingly function as complementary or lead compounds within integrated biomedical platforms. Their renewable origin, chemical

complexity, and multi-target biological activity make them particularly attractive in infection control, tissue regeneration, and advanced drug delivery systems.

Among plant-derived bioactives, herbal essential oils (HEOs) represent a distinctive and chemically complex class composed primarily of volatile terpenoid constituents.^{2,3} Their multi-component architecture enables broad-spectrum biological activity through membrane perturbation, enzyme modulation, redox regulation, and host immune interaction.^{4,5} This intrinsic multifunctionality underlies their growing application in wound management, antimicrobial coatings, antiseptic systems, and adjunct therapeutic formulations. In addition, their biodegradability and renewable sourcing align with sustainability-driven biomedical innovation.

The renewed scientific and industrial interest in HEOs is driven by converging factors: rising antimicrobial resistance, demand for safer excipients, and advances in extraction technologies, analytical chemistry, and formulation science. At the same time, sustainability initiatives and consumer expectations

^a Unit of Innovative Food Packaging and Biomaterials, School of Agro-Industry, Mae Fah Luang University, Chiang Rai 57100, Thailand.

E-mail: hk.rajabi@yahoo.com, hamid.raj@mfu.ac.th, saroat@mfu.ac.th

^b School of Medicine, Mae Fah Luang University, Chiang Rai 57100, Thailand.

E-mail: utcharaporn.kam@mfu.ac.th

^c School of Integrative Medicine, Mae Fah Luang University, Chiang Rai 57100,

Thailand. E-mail: sulukkana.noi@mfu.ac.th

^d School of Food Science and Engineering, Hainan University, Haikou 570228, China. E-mail: huang-zhaoxian@hainanu.edu.cn

^e Institute of Physiological Chemistry, Faculty of Chemistry, University of Vienna, 1010 Vienna, Austria. E-mail: marc.pignitter@univie.ac.at



for traceable, low-impact natural products encourage the adoption of HEOs when responsibly sourced.⁶ Their intrinsic multifunctionality also allows them to act not only as therapeutic agents but also as penetration enhancers or preservative alternatives.⁷ However, the popularity of “natural” ingredients necessitates rigorous safety and standardization assessment.

Despite these advantages, direct biomedical utilization of HEOs remains constrained by fundamental physicochemical and compositional limitations. Chemotype variability influenced by geographic origin, seasonal factors, and extraction conditions complicates standardization and reproducibility.^{8,9} Concurrently, high volatility, oxidative susceptibility, and poor aqueous solubility reduce stability, bioavailability, and shelf life, potentially necessitating elevated doses that increase irritation or toxicity risk.² Addressing these constraints requires formulation strategies capable of stabilizing reactive constituents while preserving biological functionality.

Encapsulation has therefore emerged as a central enabling technology for volatile phytochemicals. By entrapping HEOs within protective matrices, encapsulation mitigates environmental degradation, modulates release kinetics, improves dispersibility, and reduces exposure-associated toxicity.^{10–13} While microencapsulation provides partial protection, nanoencapsulation—typically operating at ≤ 100 nm—offers additional advantages through increased surface area, improved cellular interaction, enhanced penetration, and tunable release profiles.^{14–16}

Polymer-based nanocarriers are particularly attractive due to their structural versatility, biodegradability, and established biomedical relevance.⁴ By integrating the intrinsic bioactivity of HEOs with the controlled delivery characteristics of polymeric nanosystems, multifunctional platforms can be engineered for infection control, inflammation modulation, regenerative medicine, and targeted therapeutic delivery. Importantly, nanoencapsulation also expands potential administration routes—including topical, oral, and inhalation pathways—by enhancing mucosal adhesion, enzymatic protection, and sustained release.^{17,18} Polymeric nanoparticles—whether nanospheres or nanocapsules—allow precise control over encapsulation efficiency, release behavior, and biological performance.^{4,19} Numerous studies report significant improvements in HEO stability, dispersibility, and targeted release within polymeric matrices, translating into enhanced bioactivity and functional device integration.^{20–23}

In this review, we critically examine recent advances in polymer-based nanoencapsulation strategies for HEOs, linking formulation parameters to biological performance and translational feasibility. Beyond summarizing preparation platforms, we synthesize mechanistic insights, evaluate safety and scalability considerations, and identify the principal bottlenecks limiting clinical adoption. By integrating materials innovation with regulatory and manufacturing perspectives, this work provides a structured roadmap for advancing standardized, scalable, and clinically relevant HEO-based nanotherapeutics.

2. Overview of HEOs for biomedical applications

2.1. Definition, sources, and main bioactive components of HEOs

HEOs are chemically complex mixtures of volatile plant-derived secondary metabolites whose biological activity is largely dictated by their dominant bioactive constituents.⁵ Beyond their ecological function in plant defense against pathogens, herbivores, and environmental stressors, HEOs have been widely applied in pharmaceutical, cosmetic, and food systems.² Their composition is strongly influenced by extraction methodology, with conventional techniques such as hydrodistillation and steam distillation increasingly complemented by advanced approaches including supercritical CO₂ and microwave-assisted extraction, each of which can alter yield, volatility retention, and chemical integrity.³

Although HEO-producing species span diverse botanical families—including Lamiaceae, Rutaceae, Myrtaceae, Apiaceae, Lauraceae, Cupressaceae, Pinaceae, Zingiberaceae, and Asteraceae²⁴—their biomedical relevance is governed less by taxonomy and more by chemotype. Geographic origin, genetic background, cultivation conditions, climate, and developmental stage collectively shape compositional variability.²⁵ These oils are biosynthesized and accumulated in specialized secretory structures such as glandular trichomes, resin ducts, and oil glands,^{26,27} and improper harvesting or post-harvest handling may significantly modify the resulting chemical fingerprint. Consequently, botanical source and processing conditions directly affect downstream formulation reproducibility.

Chemically, HEOs are dominated by terpenoids and phenylpropanoids, biosynthetically derived from isoprenoid precursors (C₅ units), which largely determine their antimicrobial, antioxidant, and anti-inflammatory behavior.²⁸ Minor constituents—including oxygenated derivatives such as alcohols, aldehydes, ketones, and esters—often modulate overall activity through synergistic or antagonistic interactions. This multicomponent architecture underlies both the therapeutic potential and the standardization challenges associated with HEO-based biomedical systems.

2.2. Key biological properties relevant to biomedical applications

HEOs exhibit diverse biological activities that underpin their biomedical relevance. Importantly, their therapeutic versatility often arises from synergistic (“entourage”) interactions among major and minor constituents, which may enhance or modulate bioactivity relative to isolated compounds.²⁹ Rather than acting through single molecular targets, HEOs typically exert multi-pathway effects, making them particularly suitable for complex pathological conditions involving infection, oxidative stress, inflammation, and dysregulated cell proliferation (Fig. 1).

2.2.1. Antimicrobial, anti-biofilm, and wound healing. The antimicrobial activity of HEOs is primarily attributed to their lipophilic constituents, which integrate into microbial membranes, disrupt lipid bilayer integrity, increase permeability,






Fig. 1 Overview of HEOs for biomedical applications.

and cause leakage of intracellular contents. Additional mechanisms include interference with energy metabolism, efflux pump inhibition, and suppression of quorum sensing and biofilm formation.^{30–33} These membrane-targeted effects explain their broad activity against Gram-positive and Gram-negative bacteria, as well as fungi.³⁴

Beyond infection control, HEOs support wound healing through integrated mechanisms involving antimicrobial protection, modulation of local inflammation, and stimulation of cellular proliferation and angiogenesis. By simultaneously addressing microbial burden and inflammatory imbalance, they facilitate progression through the inflammatory, proliferative, and remodeling phases of healing.^{20,32,35} Such multifunctionality makes HEOs particularly attractive for incorporation into advanced wound dressings and polymeric delivery systems.

2.2.2. Antioxidant properties. The antioxidant capacity of HEOs is closely linked to their terpenoid and phenolic constituents and depends on both chemical composition and analytical methodology.³⁶ Mechanistically, HEOs scavenge reactive oxygen species (ROS), inhibit lipid peroxidation, donate hydrogen atoms to interrupt radical chain reactions, and enhance endogenous antioxidant defenses. By mitigating oxidative damage to lipids, proteins, and nucleic acids, they may contribute to protection against aging-related disorders, inflammatory conditions, and carcinogenesis.

Numerous plant-derived HEOs have demonstrated measurable antioxidant activity *in vitro*.^{23,37–42} However, biological efficacy *in vivo* is strongly influenced by stability, bioavailability, and controlled release—parameters that nanoencapsulation strategies aim to optimize.

2.2.3. Anti-inflammatory activity. Inflammation involves activation of pattern-recognition receptors and downstream signaling cascades that promote cytokine production and leukocyte recruitment.⁴³ Central pathways—including NF- κ B, MAPKs, JAK/STAT, and COX-mediated eicosanoid synthesis—amplify inflammatory signaling. HEOs attenuate these processes by suppressing pro-inflammatory mediators such as TNF- α , IL-6, COX-2, and iNOS, while reducing oxidative stress and immune cell infiltration.^{44,45}

Experimental evidence supports these mechanisms across both *in vitro* and *in vivo* models. For example, nanoformulated tea tree oil has demonstrated enhanced clinical performance in inflammatory skin conditions when combined with conventional therapeutics.⁴⁶ Similarly, essential oil-based hydrogel systems have been shown to regulate ROS production, angiogenesis, cytokine expression, and macrophage polarization in wound-healing models.^{47,48} These findings underscore the relevance of delivery systems in amplifying anti-inflammatory efficacy.

2.2.4. Anticancer activities. HEOs exert anticancer effects through multi-target mechanisms, including inhibition of



proliferation, induction of apoptosis, cell-cycle arrest, anti-angiogenesis, and suppression of metastatic signaling.⁴⁹ These actions involve modulation of mitochondrial pathways, MAPK and PI3K/AKT/mTOR signaling, and transcription factors such as NF- κ B and STAT3. Importantly, the multicomponent composition of HEOs enables simultaneous interference with complementary oncogenic pathways.

In addition to intrinsic cytotoxic effects, HEOs may potentiate conventional chemotherapeutics, enhancing efficacy or reducing adverse effects.^{23,49} Activity has been reported across diverse cancer cell models,^{50–52} with synergistic interactions among constituents contributing to enhanced potency relative to isolated compounds.

3. Stability challenges associated with HEOs

Although HEOs demonstrate considerable pharmacological promise, their biomedical translation is fundamentally limited by interconnected physicochemical instabilities that compromise reproducibility, efficacy, and safety (Fig. 2). These constraints arise not from a single vulnerability, but from a convergence of volatility, lipophilicity, chemical reactivity, and compositional variability.

Volatility represents one of the most immediate challenges. Many dominant constituents—particularly monoterpenes and

low-molecular-weight aldehydes—exhibit high vapor pressures and readily evaporate under ambient or moderately elevated temperatures. Progressive volatilization results in quantitative loss of active components, altered chemical ratios, diminished therapeutic potency, and shortened shelf life, thereby complicating dose standardization in topical, oral, and systemic formulations.⁴

Compounding this issue, the intrinsic lipophilicity of HEOs limits their dispersion in aqueous biological environments and hydrophilic pharmaceutical matrices. Poor aqueous solubility restricts bioavailability and reduces effective concentration at target tissues, often necessitating higher administered doses that may increase irritation risk.

Chemical degradation further exacerbates instability. Exposure to oxygen initiates oxidative reactions that generate peroxides and reactive intermediates, particularly in unsaturated terpenoids, phenolic compounds, and aldehydes.⁵³ These transformations can lead to discoloration, loss of aroma, reduced biological activity, and formation of sensitizing or toxic by-products. In parallel, ultraviolet radiation promotes photoisomerization and molecular fragmentation, while thermal stress during processing or storage may induce hydrolysis, rearrangement, or cyclization reactions that modify chemical integrity and biological performance.⁵⁴ Collectively, these degradation pathways alter both safety and efficacy profiles over time.




Fig. 2 Stability challenges associated with HEOs.



Formulation-dependent factors such as pH also influence stability. Acidic or alkaline environments can accelerate hydrolytic reactions, modify solubility characteristics, or promote structural transformation of sensitive constituents.⁵⁵ Therefore, maintaining physicochemical compatibility between HEOs and delivery matrices is critical for therapeutic reliability.

Beyond formulation parameters, upstream biological and agricultural variables significantly shape stability outcomes. Plant species, chemotype, harvested organ, and developmental stage determine baseline chemical composition, while geography, climate, and soil conditions modulate biosynthetic pathways and metabolite ratios.²⁵ Post-harvest handling and extraction methods introduce additional variability: delayed processing may permit enzymatic conversion of volatile constituents, and high-temperature or solvent-intensive extraction can generate artifacts that deviate from native chemical profiles.⁵⁶

4. Polymer-based nanoencapsulation of HEOs

The application of polymeric nanocarriers for HEO delivery is fundamentally driven by the need to stabilize volatile phytochemicals while enabling controlled therapeutic performance (Fig. 3).

By forming nanoscale protective reservoirs, polymer matrices shield labile constituents from oxidation, volatilization, and photodegradation, thereby improving physicochemical stability, aqueous dispersibility, and biological efficacy.⁵⁷ Beyond passive protection, polymeric systems allow programmable release kinetics, enhanced tissue retention, and improved bioavailability under physiological conditions.

4.1. Natural polymers: biofunctionality and synergy

Natural and biodegradable polymers are particularly attractive for HEO nanoencapsulation due to their intrinsic biocompatibility, biodegradability, and often mucoadhesive or bioactive properties.⁵⁸ Importantly, certain natural polymers contribute complementary therapeutic effects. For example, chitosan exhibits inherent antimicrobial and hemostatic activity, while gelatin offers excellent biocompatibility and film-forming capacity (Tables 1 and 2). Such synergy enhances the overall therapeutic performance of the composite system.

This integrative approach is exemplified by polyethylene oxide–gelatin nanofibers incorporating *Myrtus communis* L. essential oil, which demonstrated a biocompatible scaffold for antimicrobial wound management.⁵⁹ In such systems, the polymer provides structural integrity and sustained release, while the encapsulated HEO delivers bioactive functionality.




Fig. 3 Polymer-based nanoencapsulation of HEOs.



Table 1 Protein-based polymers used for encapsulation of HEOs

Protein	Sources	IEP ^a	Key properties	Applications in encapsulation methods	Ref.
Gelatin	Collagen (animal skin, bones, fish scales)	4.7–9.5 (type A/B)	Biocompatible, biodegradable, film-forming, good emulsifier, thermoreversible gelation	Hydrogel, nanoemulsion, and electrospinning methods for encapsulating HEOs such as <i>Litsea cubeba</i> , oregano, <i>Ferula assa-foetida</i> , and <i>Myrtus communis</i> L. EOs	32, 36 and 59
Whey protein isolate (WPI)	Milk (dairy by-product)	4.5–5.2	Amphiphilic, antioxidant, good emulsifier, film-forming	Nanoemulsion for encapsulating HEOs such as <i>Litsea cubeba</i> and <i>Cinnamomum cassia</i>	36
β-Lactoglobulin (β-LG)	Whey protein (milk)	5.1–5.3	Globular protein with hydrophobic binding pockets; high affinity for lipophilic compounds	Complex coacervation and self-assembly for encapsulating HEOs such as black pepper	67
α-Lactalbumin (α-LA)	Milk (whey fraction)	4.2–4.5	Calcium-binding, heat-stable, and good surface-active	Emulsion for encapsulating HEOs such as l-menthol and chamomile	68 and 69
Bovine serum albumin (BSA)	Bovine blood serum	4.7–5.3	High binding affinity, antioxidant, biocompatible	Complex coacervation and antisolvent precipitation methods for encapsulating HEOs such as peppermint, thymol	70 and 71
Soy protein isolate (SPI)	Soybeans	4.5–5.0	Cost-effective, good emulsifying ability, thermal stability	Emulsion and antisolvent precipitation for encapsulating HEOs such as citrus and <i>Litsea cubeba</i>	72
Pea protein isolate (PPI)	Yellow peas	4.5–5.0	Sustainable plant protein, good emulsification and film-forming ability	Antisolvent precipitation and electrospinning for encapsulating HEOs such as hyssop and cumin	73
Zein	Corn (prolamin fraction)	6.2–6.8	Hydrophobic, film-forming, biodegradable, ethanol-soluble	Electrospinning for encapsulating HEOs such as rosemary and oregano	39 and 74
Casein	Milk	4.6–4.8	Amphiphilic, micelle-forming, excellent carrier for hydrophobic compounds	Self-assembly and electrospinning systems for encapsulating HEOs such as ginger and oregano	75 and 76
Collagen	Animal connective tissue	~9.0	Biocompatible, structural integrity, film-forming	Electrospinning and emulsion systems for encapsulating HEOs such as lemon and dill, and palmarosa	77 and 78
Silk fibroin	Silkworm cocoons (<i>Bombyx mori</i>)	4.2–4.5	Biocompatible, mechanically strong, slow-degrading	Electrospinning and self-assembly systems for encapsulating HEOs such as oregano and eugenol	79 and 80
Lactoferrin	Milk	8.0–9.0	Cationic, mucoadhesive, metal-binding, broad spectrum of antimicrobial activities	Complex coacervation and pickering emulsion systems for encapsulating HEOs such as black pepper and clove	

^a IEP: isoelectric point.

Table 2 Polysaccharide-based polymers used for encapsulation of HEOs

Polysaccharide	Source	IEP ^a	Key properties	Use in encapsulation methods	Encapsulated HEOs	Ref.
Chitosan	Derived from chitin (crustacean shells, fungal cell walls)	~6.3	Cationic, mucoadhesive, biocompatible, antimicrobial, film-forming	Ionic gelation, emulsification, coacervation, spray drying	Green tea, <i>Rosmarinus officinalis</i>	30 and 81
Alginate	Brown algae (e.g., <i>Laminaria</i> , <i>Macrocystis</i>)	—	Anionic, biocompatible, gel-forming with Ca ²⁺ ions	Ionotropic gelation, emulsion, coacervation	<i>Satureja khuzestanica</i> , <i>Zingiber officinale</i>	82 and 83
Pectin	Citrus peel, apple pomace	—	Anionic, biodegradable, good gelling and film-forming capacity	Emulsification, complex coacervation, liposome	Lemongrass, rose	84 and 85
Starch and modified starch	Corn, potato, tapioca	—	Good encapsulant, digestible, low cost	Spray drying, electrospinning, nanoprecipitation	Thyme, ginger	86 and 87
Gum arabic	Acacia tree exudate	—	Emulsifier and film former, soluble in water	Emulsion, spray drying, complex coacervation, nanoprecipitation	Eucalyptus, lemongrass	88 and 89
Carrageenan	Red seaweeds (<i>Kappaphycus</i> , <i>Eucheuma</i>)	—	Anionic, gel-forming, biocompatible	Emulsification, hydrogels	Carvacrol	90
Dextran	Bacterial fermentation (<i>Leuconostoc mesenteroides</i>)	—	Neutral, water-soluble, biocompatible	Emulsion, hydrogel	<i>Alpinia zerumbet</i> Fructus, <i>Eucalyptus</i>	91 and 92
Polyglutamic acid	Bacterial fermentation (<i>Bacillus</i> species)	—	Neutral, water-soluble, biodegradable, biocompatible, anionic	Liposome	<i>Alpinia galanga</i>	93

^a IEP: isoelectric point.



4.2. Synthetic and smart polymers: precision and scalability

Synthetic polymers—including poly(lactic-co-glycolic acid), polyethylene glycol, and polycaprolactone—offer precise control over degradation rate, mechanical strength, and release behavior, supporting reproducible large-scale manufacturing (Table 3). Their networks can be engineered to optimize encapsulation efficiency and diffusion kinetics while enabling stimulus-responsive behavior.⁵⁷ Hybrid systems integrating natural biopolymers with synthetic polymers often achieve an optimal balance between intrinsic bioactivity and structural tunability, improving batch reproducibility and translational feasibility.

4.3. Encapsulation platforms: functional classification

Polymer-based nanoencapsulation approaches can be conceptually classified according to their formation mechanisms rather than enumerated individually (Table 4). Emulsification-driven systems, including solvent evaporation and nanoemulsion methods, rely on interfacial stabilization of dispersed oil droplets within polymeric matrices. In contrast, precipitation-based techniques such as nanoprecipitation exploit polymer self-assembly during solvent exchange to entrap volatile constituents. Electrohydrodynamic processes, including electrospinning and electrospraying, enable fabrication of nanofibrous scaffolds or particulate carriers with high surface-area-to-volume ratios, particularly advantageous for wound-healing and topical systems. Polyelectrolyte-based strategies such as ionic gelation and complex coacervation utilize electrostatic interactions to form structured matrices capable of modulating release kinetics. Finally, post-processing stabilization techniques—including spray-drying and freeze-drying—convert colloidal nanosystems into solid-state dosage forms suitable for storage and industrial handling.^{60,61}

4.4. Design-oriented selection framework

Selection of polymer type and fabrication strategy should be guided by a rational design framework that aligns the physicochemical vulnerabilities of the HEO with the structural characteristics of the carrier. Highly volatile and oxidation-sensitive oils may benefit from dense or crosslinked polymer matrices that restrict oxygen diffusion and vapor loss. Oils with poor aqueous solubility require systems that enhance dispersion while maintaining release control. Application-specific requirements further shape formulation decisions: topical wound-healing systems often prioritize film-forming or nanofibrous architectures, whereas oral or inhalable systems demand mucoadhesive or diffusion-regulated platforms.^{62–66} Thus, effective nanoencapsulation is not method-driven but problem-driven, integrating oil chemistry, polymer properties, and therapeutic intent into a unified formulation strategy.

4.5. Mechanistic basis of biological effects in polymer-encapsulated HEO systems

Polymer-based nanoencapsulation enhances the biological performance of HEOs through a multi-level mechanistic framework integrating: (i) intrinsic phytochemical bioactivity, (ii) polymer-mediated physicochemical modulation, and (iii) nano-bio interfacial interactions that govern diffusion, cellular uptake, and release kinetics. Rather than functioning as passive reservoirs, polymeric nanocarriers actively regulate structure-property-function relationships that shape therapeutic outcomes.

4.5.1. Intrinsic bioactivity of encapsulated HEOs. The fundamental biological activity of encapsulated HEOs remains rooted in their phytochemical composition. Antimicrobial effects are primarily mediated by lipophilic terpenoids that partition into microbial lipid bilayers, increasing membrane permeability, promoting leakage of intracellular contents,

Table 3 Synthetic and semi-synthetic polymers used for encapsulation of HEOs

Polymer	Type	Key properties	Use in encapsulation methods		Ref.
PLGA (poly(lactic-co-glycolic acid))	Synthetic copolymer	Biodegradable, FDA-approved, controlled drug release	Emulsification-solvent evaporation technique	<i>Boswellia sacra</i> oleo gum resin, lavender	94 and 95
PLA (polylactic acid)	Synthetic	Biodegradable, hydrophobic, good mechanical stability	Electrospinning	Lavender, Perilla	96 and 97
PCL (polycaprolactone)	Synthetic	Semi-crystalline, slow degradation rate, hydrophobic	Electrospinning	<i>Blumea balsamifera</i> , <i>Mentha longifolia</i>	35 and 98
Eudragit [®] (methacrylate copolymer)	Semi-synthetic	pH-sensitive, tailored release profile	Spray drying, nanoprecipitation	Oregano	99
PVA (polyvinyl alcohol)	Synthetic	Water-soluble, film-forming, stabilizing agent	Electrospinning	Tea tree, limonene	100 and 101
PEG (polyethylene glycol)	Synthetic	Hydrophilic, improves solubility and biocompatibility	Nanoliposome, pickering emulsion/nanogel	Lemongrass, <i>Atractylodes macrocephale</i>	102 and 103
Ethyl cellulose	Semi-synthetic	Hydrophobic, film-forming, provides sustained release	Hydrogel, electrospinning	<i>Cuminum cyminum</i> , ginger	76 and 104
PVP (polyvinylpyrrolidone)	Synthetic	Amphiphilic, enhances solubility, good film former, and biocompatibility	Electrospinning	Oregano	32
Polyacrylic acid (carbopol)	Synthetic	Calcium-binding, biocompatible, biodegradable, mucoadhesive properties, high water absorption capacity	Electrospinning, nanogel	<i>Pectis brevipedunculata</i> , <i>Lavandula angustifolia</i> Mill.	105 and 106
Polyacrylamide	Synthetic	Water-soluble, biocompatible, biodegradable, gelling properties	Pickering emulsion/hydrogel	Lavender	107





Table 4 Summary of polymer-based nanoencapsulation techniques used for HEOs

Encapsulation technique	Principle/process description	Materials/solvents	Key features and advantages	Nanoencapsulated HEOs	Ref.
Nanoemulsion	Formation of thermodynamically unstable but kinetically stable emulsions with droplet sizes in the nanometer range (20–200 nm). The EO is dispersed as fine droplets stabilized by surfactants, preventing coalescence and volatilization.	Oil phase: EOs or lipids; aqueous phase: water or buffer; surfactants: Tween, Span 80, lecithin; co-surfactants: ethanol, glycerol, propylene glycol. Polymers: chitosan, alginate, pectin, gelatin, whey protein, casein, gum arabic, synthetic polymers: PVA, PEG	High kinetic stability, transparency, enhanced solubility and bioavailability, protection against oxidation and volatilization, suitable for thermolabile oils, and allows controlled or sustained release.	Lavender, <i>Artemisia annua</i> , <i>Aniba canellilla</i> (Kunth) Mez, <i>Foeniculum vulgare</i> Mill., oregano, and perilla, lemongrass, <i>Thymus daenensis Celak</i> and <i>Bunium persicum</i> .	108–110
Nanoprecipitation (solvent displacement)	A water-miscible organic phase (polymer + EO) is injected into an aqueous stabilizer phase; rapid solvent diffusion causes polymer precipitation and nanoparticle formation; requires polymer solubility in organic solvent and insolubility in water.	Solvents: acetone, ethanol; polymers: sodium caseinate, chitosan, whey protein isolate, poly-ε-caprolactone, zein; surfactants: Tween 80, PVA	Simple, low-energy, reproducible; avoids high temperature and shear; ideal for thermolabile oils.	Guava leaf, oregano, curry leaf, lemongrass	111 and 112
Complex coacervation and ionic gelation	Electrostatic interactions between oppositely charged biopolymers (coacervation) or between a polyelectrolyte and multivalent counterion (ionic gelation) form nanocapsules.	Polymers: gelatin, chitosan, alginate, gum arabic, soy protein isolate, whey protein isolate; ions: sodium tripolyphosphate	Organic-solvent-free, biocompatible, and mild; ideal for heat-sensitive oils; good control of release properties.	<i>Nepeta hormozganica</i> , <i>Nepeta dschuprensis</i> , zeylanicum, <i>Cyperus articulatus</i> rhizome, carvacrol, green tea, <i>Cynometra cauliflora</i>	81 and 113
Liposomal entrapment	EO components are entrapped within phospholipid bilayers or aqueous cores of liposomes prepared via thin-film hydration, ethanol injection, or microfluidics.	Phospholipids (lecithin, phosphatidylcholine), cholesterol	Biocompatible, biodegradable, enhances solubility and bioavailability; protects from oxidation and volatilization.	Tea tree, <i>Zhumeria majdae</i> , lemongrass,	102 and 114
Molecular inclusion	Essential oil molecules form host-guest complexes within cyclodextrin cavities via non-covalent interactions (hydrophobic and van der Waals forces).	Cyclodextrins (α -, β -, γ -CD, HP- β -CD)	Solvent-free; enhances solubility, stability, and controlled release; food-grade; improves volatility control and photostability	Bergamot, rosemary, thymol, D-limonene, coriander, eugenol and cinnamaldehyde	115 and 116
Microfluidics	Precise mixing of polymer, essential oil, and stabilizer phases within micro-channels enables controlled nanoparticle formation via laminar flow and solvent diffusion.	Chitosan, alginate, hyaluronic acid, PNIPAM	Highly reproducible; continuous, scalable; offers precise control over size distribution (<10% PDI) and morphology; low solvent use.	Frankincense, eugenol, linalool, and geraniol, mint oil	117 and 118
Hydrogels (nanogels)	Hydrophilic polymer networks cross-linked at the nanoscale entrap EOs through electrostatic/hydrophobic interactions.	Water or buffer; polymer + EO	High water content, biocompatible, stimuli-responsive release; stable and protective.	<i>Bunium persicum</i> , lavender, thymus vulgaris, <i>Syzygium aromaticum</i>	108 and 119
Emulsification-solvent evaporation and emulsion diffusion-solvent evaporation	A polymer and EO are dissolved in a volatile organic solvent and emulsified in an aqueous surfactant phase (O/W); solvent evaporation induces polymer precipitation around oil droplets forming nanocapsules.	Dichloromethane, ethyl acetate; polymers (PLGA, ethyl cellulose); surfactants (PVA, Tween)	Produces uniform nanoparticles; suitable for hydrophobic oils; good encapsulation efficiency; protects against oxidation and volatilization.	Garlic, <i>Hypericum perforatum</i> , <i>Boswellia sacra</i> Oleo gum resin, lavender, <i>Nigella sativa</i>	94 and 95
Spray-drying and freeze-drying	Emulsions containing EOs are spray- or freeze-dried to form powders.	Polymers: maltodextrin, gum arabic, starch, whey protein	Scalable, cost-effective, and versatile; preserves volatile oils.	<i>Cinnamodendron dinisii</i> , lemon grass, <i>Mentha pulegium</i> , <i>Nepeta crispa</i> , oregano	89 and 120

Table 4 (continued)

Encapsulation technique	Principle/process description	Materials/solvents	Key features and advantages	Nanoencapsulated HEOs	Ref.
Electrospinning and electrospinning	A polymer-oil solution is subjected to a high-voltage field Electrospinning → nanofibers Electrospinning → nanoparticles	Soy protein isolate, pea protein isolate, gum arabic, whey protein isolate, gelatin, gellan, poly vinyl alcohol.	Solvent-based but mild; produces dry, porous structures; suitable for thermolabile compounds.	Perilla, <i>Zataria multiflora</i> , Satureja and thyme	97 and 121
Fluidized bed drying	Droplets or particles containing EOs are suspended in an upward flow of moderate temperature air, creating a “fluidized” state that. It is used to dry emulsions or to apply polymer coatings onto pre-formed particles or granules containing EOs. Mostly used for micro-encapsulation, rarely nanoparticles.	Feed may be an emulsion or suspension containing EO and wall materials; optional coating solvents may include ethanol or water. Polymers: maltodextrin, gum arabic, modified starch, cellulose derivatives, alginate, chitosan, whey protein concentrate, zein.	Produces free-flowing, dry micro/nanoparticles; offers good retention of volatile oils; scalable and continuous; enables controlled-release coating; suitable for heat-sensitive EOs due to short drying time and efficient heat transfer.	Bitter orange	122

disrupting energy metabolism, and interfering with efflux systems.^{123–125}

In anticancer applications, encapsulated constituents induce mitochondrial dysfunction, excessive ROS generation, and caspase-dependent apoptosis, accompanied by modulation of BAX/BCL-2 ratios and suppression of survival signaling pathways including PI3K/AKT, mTOR, and STAT3.^{126,127}

Anti-inflammatory activity involves attenuation of cytokine cascades (TNF- α , IL-6, IL-1 β), downregulation of COX-2 and iNOS, and inhibition of NF- κ B-mediated transcriptional signaling.^{43,128} Concurrently, antioxidant mechanisms contribute to redox homeostasis through scavenging of reactive species, suppression of lipid peroxidation, and upregulation of endogenous defense systems, thereby mitigating oxidative stress associated with chronic inflammation and impaired tissue repair.^{129,130}

Encapsulation does not fundamentally alter these intrinsic mechanisms; rather, it preserves and potentiates them by stabilizing reactive constituents and optimizing local concentration profiles.

4.5.2. Polymer-mediated physicochemical regulation. Polymeric matrices actively shape biological responses by modulating surface charge, particle size, degradation dynamics, and release kinetics.¹³¹ Surface chemistry plays a particularly critical role: cationic polymers such as chitosan promote electrostatic interactions with negatively charged bacterial membranes and cancer cell surfaces, enhancing adhesion and facilitating membrane destabilization.

Release behavior—governed by diffusion-controlled (Fickian) transport or polymer degradation—maintains therapeutic concentrations while reducing burst-associated toxicity. Mucoadhesive polymers prolong local retention at mucosal or wound sites, whereas hydrogel and nanogel networks create hydrated microenvironments that support tissue regeneration and sustained diffusion.^{132,133}

Electrospun nanofibrous matrices, characterized by high surface-area-to-volume ratios and tunable porosity, enable uniform bioactive distribution and enhanced surface exposure.¹³⁴ Synthetic polymers such as poly(lactic-co-glycolic acid) and polycaprolactone provide predictable degradation kinetics, enabling temporal control over essential oil release and improving dosing reproducibility.

4.5.3. Nano-bio interfacial and synergistic effects. At the nanoscale, reduced particle dimensions increase surface-area-to-volume ratios and intensify diffusion gradients, facilitating deeper penetration into biofilms and tumor microenvironments.¹³¹ Positive zeta potential enhances electrostatic interactions with microbial biofilm matrices and promotes endocytic internalization by mammalian cells.

Encapsulation further preserves pharmacological integrity by protecting volatile terpenoids from oxidative and photochemical degradation. Beyond stabilization, co-encapsulation strategies enable compositional synergy, spatial co-localization of active agents, and coordinated release profiles that amplify therapeutic outcomes.^{135,136}

The convergence of controlled release, enhanced permeability, polymer-cell interactions, and phytochemical synergy results in



amplified antimicrobial, anti-inflammatory, wound-healing, and anticancer efficacy relative to free HEOs. Collectively, these interconnected mechanisms position polymer nanoencapsulation not merely as a protective strategy, but as an active regulator of biological performance through rational modulation of structure–property–function relationships.

5. Structure–property–function relationships in polymer-encapsulated HEO systems

The therapeutic performance of nanoencapsulated HEOs arises from quantifiable material parameters rather than solely from intrinsic phytochemical potency. Encapsulation efficiency, transport behavior, cellular uptake, and biological efficacy are governed by polymer chemistry, network architecture, interfacial characteristics, and environmental responsiveness. Establishing direct structure–property–function correlations enables predictive formulation design and advances HEO delivery from empirical optimization toward mechanism-driven materials engineering.

5.1. Polymer chemistry and encapsulation thermodynamics

At the molecular scale, encapsulation efficiency (EE) is dictated by polymer–oil thermodynamic compatibility, molecular weight (M_w), degree of deacetylation (DD) in chitosan-based systems, and crosslink density (ρ_x). Increasing M_w enhances chain entanglement, while higher DD increases charge density and electrostatic interactions, strengthening oil retention within the matrix. Similarly, elevated ρ_x reduces network free volume and limits diffusion of oil toward the particle surface during processing.^{137–141}

Comparative studies illustrate this dependency. Starch nanofibers achieved EE values of 99.1–99.8% for thyme oil,⁸⁶ whereas zein nanofibers showed 75.23%.¹⁴² In oregano essential oil complex coacervates, hemp protein isolate–gum Arabic systems reached 57% EE,¹⁴³ compared with 95% for chitosan/gum arabic matrices.¹⁴⁴ These differences reflect variations in polymer–terpenoid affinity, interfacial stabilization capacity, and matrix compactness. Insufficient polymer–oil compatibility promotes surface migration and accelerated initial release, ultimately reducing effective dose delivery.¹⁴⁵

5.2. Physicochemical properties and nano–bio interactions

Particulate-scale parameters translate molecular design into biological performance. Particle diameter governs diffusion path length and interfacial area; nanocarriers for targeted delivery commonly fall within the 10–50 nm range.¹⁴⁶ Reduction in particle size increases surface-to-volume ratio, shortens diffusion pathways, and enhances tissue penetration. Uniformity is equally critical: a polydispersity index below 0.3 minimizes aggregation and ensures reproducible exposure kinetics.

Surface charge links colloidal stability with cellular interaction. Absolute zeta potential values of approximately ± 30 mV confer electrostatic stabilization, whereas positively charged carriers enhance adhesion to negatively charged bacterial

membranes and epithelial surfaces.¹⁴⁷ This interaction facilitates endocytic uptake and increases intracellular accumulation of volatile terpenoids. Ligand functionalization, such as folate or hyaluronic acid conjugation, introduces receptor-mediated internalization pathways, enabling selective cytotoxicity in receptor-overexpressing cells and improving therapeutic index.^{148,149}

5.3. Transport kinetics and quantitative modeling

Release kinetics provide the mechanistic bridge between structure and therapeutic outcome. The effective diffusion coefficient (D_{eff}) is inversely related to crosslink density and directly influenced by mesh size and matrix tortuosity. Highly crosslinked networks restrict solvent penetration and reduce D_{eff} , promoting sustained release, whereas loosely organized matrices permit rapid diffusion and early-stage release acceleration.^{150,151}

Diffusion-dominated transport has been consistently reported in multiple HEO-loaded delivery systems. Application of the Korsmeyer–Peppas model ($M_t/M_\infty = kt^n$) frequently yields diffusional exponent (n) values that depend heavily on the matrix geometry: the theoretical limit for ideal Fickian diffusion is $n = 0.45$ for cylindrical structures (*e.g.*, nanofibers) and $n = 0.43$ for spherical structures (*e.g.*, micro/nanoparticles).¹⁵²

For example, examining the release behavior of a multi-component HEO blend (oregano, rosemary, and *Hypericum* oils) across different carrier architectures highlights this geometric dependence.¹⁵³ Electrospun matrices exhibited $n \approx 0.436$, which closely aligns with the ideal Fickian limit for cylindrical fibers. In stark contrast, spray-dried and freeze-dried particles showed markedly lower values (n 0.299 and 0.287, respectively), indicating a transition to a “pseudo-Fickian” diffusion mechanism. This substantial deviation from the spherical limit (0.43) is driven by the intrinsic physical properties of the matrices produced by these techniques. Specifically, rapid solvent evaporation during the spray-drying process often leads to early crust formation, leaving a fraction of unencapsulated core trapped at or near the particle surface.¹⁴ This physical phenomenon, combined with the inherently high size polydispersity of such particles, triggers a pronounced initial burst release that mathematically skews the overall kinetic curve and drives the n values significantly downward.

Similarly, in a cyclodextrin inclusion system encapsulating an equimolar essential oil mixture (clove, cardamom, cinnamon, and black pepper), diffusion rate constants ($k_2 \approx 0.027$ – 0.032) substantially exceeded relaxation-associated constants ($k_1 \approx 10^{-26}$), supporting a predominantly diffusion-governed release mechanism within structurally stable matrices.¹⁵⁴

Importantly, systems exhibiting controlled Fickian diffusion ($n \leq 0.45$) are frequently associated with reduced MIC and IC₅₀ values relative to free EO formulations, as sustained exposure maintains intracellular concentrations within the therapeutic window and mitigates premature volatilization or degradation.¹⁵⁵

Stimuli-responsive chemistries further illustrate tunable structure–function coupling. Schiff base-linked hydrogels released 37.6% of *Litsea cubeba* and cinnamon EOs at pH 7.2 but 82.1% at pH 5.5, while temperature-responsive starch



carriers released 48.7% at 4 °C and only 3.5% at 25 °C within 120 min.¹⁵⁶ These environmentally induced changes in network ionization, hydration, and permeability demonstrate how polymer chemistry governs on-demand release behavior.

5.4. Matrix degradation and gastric stability

For oral delivery systems, enzymatic resistance constitutes a critical structure–function determinant. Matrix degradation depends on pore size, chain rigidity, and isoelectric properties. In uncoated Ca–alginate hydrogels with pore diameters of 10–20 nm, rapid penetration of pepsin (hydrodynamic radius \approx 3 nm) accelerates structural disintegration and premature EO release. The addition of a chitosan coating mitigates this vulnerability through a synergistic structural mechanism. The electrostatic complexation between cationic chitosan and anionic alginate forms a highly dense, tightly packed polyelectrolyte membrane at the particle surface. This interfacial layer significantly reduces the effective surface pore size, acting primarily as a physical barrier that sterically hinders the inward diffusion of pepsin. Furthermore, this robust electrostatic network limits polymer chain mobility and prevents excessive matrix swelling in acidic gastric conditions, thereby enhancing overall enzymatic resistance and preserving matrix integrity prior to intestinal transit.^{157,158}

Protein-based matrices demonstrate similar structure-dependent behavior: compact globular conformations exhibit greater resistance to proteolysis than flexible, open networks, thereby improving gastric stability and subsequent intestinal bioavailability.¹⁵⁸ Polymer architecture therefore directly regulates degradation kinetics, release timing, and systemic exposure.

5.5. Translation to biological outcomes

Biological efficacy—including reductions in MIC against biofilms or IC_{50} in tumor models—emerges from engineered exposure dynamics rather than intrinsic potency alone. Nano-scale dimensions enhance uptake, positive surface charge strengthens membrane interactions, and diffusion-controlled release sustains intracellular concentrations. Conversely, inadequate crosslinking or weak polymer–oil affinity leads to rapid clearance and diminished bioactivity.

By quantitatively correlating molecular parameters (M_w , DD, ρ_x), interfacial properties (zeta potential, particle size distribution), and transport coefficients (D_{eff} , n , k) with biological endpoints, HEO delivery systems can be rationally engineered for predictable therapeutic performance. This integrated structure–property–function framework provides the rigorous materials science perspective necessary for advancing polymer-encapsulated essential oil systems toward translational maturity.

6. Multi-functional biomedical applications of encapsulated HEOs

6.1. Advanced antimicrobial, anti-biofilm, and wound-healing strategies

The escalation of antibiotic-resistant pathogens—including *Staphylococcus aureus* (*S. aureus*), *Pseudomonas aeruginosa*

(*P. aeruginosa*), *Klebsiella pneumoniae* (*K. pneumoniae*), and *Candida* spp.—together with the clinical complexity of diabetic ulcers, burn wounds, and chronic dermal infections, necessitates antimicrobial systems capable of sustained activity, biofilm penetration, and tissue-compatible delivery. Nanoencapsulation addresses these requirements by stabilizing volatile phytochemicals while enabling controlled, localized exposure profiles.

Although numerous studies report superior antimicrobial and wound-healing outcomes for nanoencapsulated HEOs compared with free oils, the extent of improvement is strongly platform-dependent. Differences in carrier architecture, encapsulation efficiency, surface charge, and release kinetics directly influence membrane interaction, biofilm diffusion, and *in vivo* tissue response. Consequently, evaluating performance solely in terms of enhanced activity is insufficient; comparative analysis of nanoarchitectural features provides clearer insight into therapeutic optimization (Fig. 4).

Distinct trends emerge across major polymeric platforms. Nanoemulsions primarily enhance antimicrobial efficacy through reduced droplet size and improved dispersion, facilitating rapid membrane penetration and short-term bactericidal action. In contrast, hydrogel and nanogel systems emphasize spatial confinement and sustained release, supporting prolonged antimicrobial exposure and improved wound microenvironment regulation—features particularly advantageous for chronic lesions. Chitosan-based nanoparticles combine controlled release with intrinsic polymer bioactivity, where electrostatic interactions with negatively charged microbial membranes amplify anti-biofilm effects beyond encapsulation alone.

These comparative distinctions highlight that antimicrobial and wound-healing enhancement is not uniform across systems but arises from specific structure–property relationships. Platform selection should therefore be guided by infection type, required duration of exposure, and translational constraints such as stability and scalability rather than by generalized reports of increased bioactivity.

6.1.1. Nanoemulsions. Nanoemulsions represent one of the most extensively investigated platforms for enhancing the antimicrobial and wound-healing performance of HEOs. Rather than the chemical identity of the oil alone, accumulated evidence indicates that therapeutic enhancement arises primarily from physicochemical restructuring at the nanoscale.

Across studies, three consistent performance trends can be identified. First, droplet size critically governs antimicrobial potency. Formulations with mean diameters below \sim 150 nm typically demonstrate superior bactericidal kinetics and improved biofilm penetration compared with larger droplets ($>$ 250 nm), even when EO composition remains constant. The increased surface curvature and interfacial area enhance membrane contact, facilitate terpenoid partitioning into lipid bilayers, and accelerate cytoplasmic leakage. These findings suggest that nanoemulsification enhances antimicrobial activity through geometric amplification of interfacial interactions rather than solely through increased chemical concentration.






Fig. 4 Multi-functional biomedical applications of encapsulated HEOs.

Second, interfacial composition and surfactant–oil balance modulate release behavior and stability. Optimized surfactant systems reduce premature volatilization and oxidative degradation while preventing excessive burst release. Encapsulation efficiency and interfacial charge further influence microbial membrane affinity, particularly against Gram-negative species with robust outer membranes. The comparatively higher resistance of *P. aeruginosa* reported in several studies⁴⁰ appears linked not to insufficient EO potency, but to its efflux capacity and dense biofilm matrix, underscoring that biological barriers interact dynamically with nanoemulsion architecture.

Third, integration into secondary polymeric matrices alters therapeutic durability. While standalone nanoemulsions provide rapid antimicrobial action due to enhanced dispersion and membrane permeation, they may exhibit limited residence time in chronic wound environments. Embedding nanoemulsions within hydrogels, nanoemulgels, or composite films improves spatial retention, sustains local EO concentration, and creates moist bioactive microenvironments that support re-epithelialization and collagen remodeling. *In vivo* studies consistently report accelerated wound contraction and enhanced angiogenesis when nanoemulsions are incorporated into structured dressings rather than applied alone.^{20,36}

Comparative evaluations further indicate that EO nanoemulsions often demonstrate superior antimicrobial performance relative to coarse emulsions and non-emulsified systems,

highlighting that droplet-scale structuring—rather than encapsulation alone—is likely a primary determinant of enhanced bioactivity.^{40,41,104,159} Emerging multi-EO nanoemulsion formulations, including binary blends of lemon and peppermint essential oils, extend this principle by leveraging compositional synergy to broaden antimicrobial spectra and, in some cases, improve anticancer activity.⁵⁰ These effects are generally attributed to cooperative chemical interactions facilitated by co-localization of bioactive constituents within nanoscale droplets.

Collectively, nanoemulsification enhances HEO performance through size-dependent membrane interaction, interfacial stabilization of volatile terpenoids, and adaptable integration into secondary delivery matrices. However, variability in reported MIC and IC₅₀ values across studies highlights the need for standardized formulation and testing protocols to enable meaningful cross-platform comparison. Thus, the therapeutic impact of nanoemulsions should be interpreted not as universally superior, but as architecture-dependent and application-specific.

6.1.2. Hydrogels (nanogels). Nanogels constitute a structurally distinct polymeric platform in which a crosslinked, hydrated network governs both retention and diffusion of encapsulated HEOs. Unlike nanoemulsions, where droplet mobility drives rapid membrane interaction, nanogels rely on network-controlled release kinetics and prolonged local



residence. Consequently, therapeutic performance is determined less by EO composition alone and more by polymer architecture, crosslinking density, swelling behavior, and polymer–EO affinity.

Across studies, two recurring therapeutic patterns emerge. First, nanogels consistently enhance antiparasitic efficacy, particularly against *Leishmania* species. Carbomer-, CMC-, and thermoresponsive polymer systems stabilize volatile antiparasitic terpenoids and facilitate sustained dermal exposure. Reports of near-complete inhibition of *Leishmania major*, *L. tropica*, and *L. amazonensis*^{105,160,161} suggest that controlled diffusion and prolonged tissue contact are critical determinants of efficacy in parasitic lesions, where continuous drug exposure is often more important than rapid concentration spikes. Thermoresponsive systems tend to induce faster initial parasite mortality due to temperature-triggered structural relaxation, whereas highly crosslinked networks favor slower yet sustained release. These differences illustrate that polymer chemistry directly modulates the balance between immediate toxicity and prolonged therapeutic exposure.

Second, in bacterial wound infections, nanogels prioritize persistence over rapid bactericidal kinetics. EO-loaded CMC, alginate, and chitosan-based systems demonstrate strong inhibition of *S. aureus* and *P. aeruginosa*,^{82,104} largely attributable to enhanced retention at the application site and gradual diffusion through biofilm matrices. Compared with nanoemulsions, which often achieve faster initial membrane disruption, nanogels typically exhibit slower onset but improved local durability—an advantage in chronic or biofilm-associated infections requiring sustained antimicrobial pressure.

An additional advantage of nanogels lies in their capacity to integrate biofunctional polymers. Chitosan-based systems, for example, combine intrinsic mucoadhesive, regenerative, and antimicrobial properties with EO activity, producing synergistic effects in cutaneous leishmaniasis models when used alongside standard therapies.¹⁶² Such hybrid systems demonstrate that polymer bioactivity can complement rather than merely deliver the encapsulated oil.

However, nanogel performance remains highly formulation-dependent. Excessive crosslinking may restrict EO diffusion despite high encapsulation efficiency, while insufficient network density can compromise sustained release. Variability in gel viscosity, swelling ratios, and assay conditions contributes to wide discrepancies in reported MIC and inhibition values, complicating cross-study comparison. Additionally, large-scale reproducibility of network architecture, sterilization compatibility, and long-term storage stability remain less characterized than for nanoemulsion systems.

Overall, nanogels offer a retention-dominant delivery strategy particularly suited for chronic dermal and parasitic conditions where sustained exposure is essential. Their therapeutic superiority is not universal but indication-specific, emerging from controlled diffusion, polymer biofunctionality, and localized persistence rather than rapid membrane-targeting alone.

6.1.3. Chitosan nanoparticles. Chitosan nanoparticles (CNPs) represent a charge-dominant delivery architecture in which

therapeutic enhancement arises not only from EO encapsulation but from intrinsic polymer bioactivity. Unlike nanoemulsions (geometry-driven) or nanogels (diffusion-governed), CNP performance is strongly dictated by electrostatic interactions between protonated amine groups and negatively charged microbial membranes or biofilm matrices. Consequently, antimicrobial amplification in CNP systems typically reflects a dual mechanism: surface charge-mediated membrane destabilization coupled with controlled EO release.

Across studies, a consistent pattern emerges in which positively charged particles (<200 nm; zeta potential commonly > +25 mV) demonstrate superior antibacterial and antifungal activity compared with neutral or anionic carriers.^{83,163} Enhanced inhibition of multidrug-resistant *Klebsiella pneumoniae*, as well as improved performance relative to alginate-based nanoparticles, underscores that surface charge density—rather than encapsulation efficiency alone—plays a decisive role in biological outcome. Systems with reduced zeta potential frequently exhibit diminished antimicrobial amplification despite comparable EO loading, reinforcing the central role of electrostatic adhesion and biofilm interaction.

CNPs also exhibit notable versatility across bacterial, fungal, and parasitic models. Broad-spectrum antibacterial, anticandidal, and antileishmanial activities have been reported for EO-loaded CNPs, often accompanied by reduced cytotoxicity relative to free oils.²¹ This improved safety profile likely arises from moderated release kinetics and spatially confined exposure. However, release behavior remains formulation-dependent: highly crosslinked particles may limit burst release but delay antimicrobial onset, whereas moderately crosslinked systems balance immediate membrane contact with sustained diffusion. Inconsistent reporting of release kinetics across studies complicates direct comparison with nanoemulsion and nanogel platforms.

In topical and wound-care applications, CNP systems benefit from chitosan's intrinsic mucoadhesive and regenerative properties. Enhanced retention on moist tissue surfaces and strong interaction with extracellular polymeric substances may improve biofilm disruption relative to low-viscosity nanoemulsions.¹¹³ Fabrication strategies—including ionic gelation, emulsion-ionic gelation, and electrospraying—further influence colloidal stability and thermal robustness, with some formulations demonstrating superior antifungal or antibacterial activity compared with free EO counterparts.^{37,164} Nonetheless, aggregation under physiological ionic strength conditions remains a recurrent limitation.

From a translational perspective, CNP reproducibility presents unique challenges. Variability in molecular weight and degree of deacetylation significantly affects particle size, zeta potential, and antimicrobial potency, complicating batch-to-batch consistency. Large-scale manufacturing requires precise control of ionic gelation parameters, while potential regulatory concerns may arise from residual crosslinkers or impurities in naturally derived chitosan sources.

Overall, CNP-based EO systems derive their therapeutic distinctiveness from electrostatic amplification and polymer–EO synergy rather than nanoscale dispersion alone. Their superiority over nanoemulsions or nanogels appears



context-dependent, particularly favoring biofilm-associated or surface-localized infections where charge-mediated adhesion is advantageous. Standardized comparative evaluations are necessary to determine whether this charge-driven architecture consistently translates into clinically meaningful benefit across infection models.

6.1.4. Electrospinning. Electrospinning represents a scaffold-based nanoencapsulation strategy in which HEOs are immobilized within solid polymeric nanofibers rather than dispersed as mobile droplets or nanoparticles. In contrast to nanoemulsions (geometry-driven membrane interaction) and chitosan nanoparticles (charge-mediated adhesion), electrospun systems derive therapeutic performance primarily from fiber morphology, porosity, and matrix–EO compatibility. Biological outcomes are therefore governed by structural parameters such as fiber diameter distribution, crystallinity, and core–shell architecture.

Across studies, two reproducible performance patterns emerge. First, electrospun fibers function as matrix-immobilized reservoirs that favor sustained antimicrobial exposure over rapid bactericidal onset. Restricted EO mobility within the solid matrix typically results in slower initial kinetics compared with nanoemulsions; however, the high surface-area-to-volume ratio and interconnected porosity enable prolonged vapor-phase and contact-mediated antimicrobial activity. This reservoir-like behavior appears particularly advantageous in chronic wound environments where continuous antimicrobial pressure and recolonization prevention are more critical than immediate concentration spikes.^{98,100,165}

Second, microstructural design strongly modulates release durability and therapeutic predictability. Core–shell architectures spatially separate EO-rich domains from mechanically supportive polymer shells, reducing burst release commonly observed in blended fibers and enabling diffusion-controlled kinetics. Comparative evaluations frequently report improved stability and extended antimicrobial performance of Ajwain EO in core–shell systems relative to homogeneous blends.¹⁶⁶ In addition to infection control, several electrospun formulations promote fibroblast adhesion, angiogenesis, and anti-inflammatory responses, reinforcing their dual function as both antimicrobial barriers and regenerative scaffolds.¹⁶⁷

Electrospun membranes also demonstrate efficacy against fungal and biofilm-associated infections, achieving substantial inhibition while maintaining mammalian cell compatibility.¹⁰¹ Unlike nanoparticle-based systems that rely on penetration into biofilm matrices, fiber-based platforms primarily exert surface-mediated and volatilization-driven effects. Although this may limit deep biofilm infiltration compared with cationic nanoparticles, it provides a stable protective interface that can prevent microbial recolonization on wound surfaces or implanted materials.

Despite these advantages, translational considerations remain significant. Uniform EO distribution within fibers can be challenging, and phase separation during spinning may compromise reproducibility. Mechanical integrity may decline at high EO loading, while large-scale electrospinning requires tight control of humidity, voltage, and flow parameters, potentially limiting industrial scalability relative to bulk nanoemulsion

preparation. Standardization of fiber morphology and long-term stability under storage conditions remains insufficiently addressed.

Overall, electrospun EO-loaded nanofibers provide a structure-controlled delivery paradigm particularly suited for sustained barrier protection and regenerative wound management. Their therapeutic advantage over droplet- or particle-based systems appears context-dependent, emerging in applications where spatial confinement and prolonged surface activity outweigh the need for rapid antimicrobial penetration.

6.1.5. Alginate nanoparticles. Alginate nanoparticles (ANPs) represent an ionic network-based encapsulation strategy in which EO retention and release are governed primarily by calcium-mediated crosslinking rather than electrostatic membrane interaction. In contrast to charge-dominant chitosan systems, alginate architectures emphasize structural stability, biocompatibility, and diffusion-controlled delivery. Therapeutic performance is therefore closely linked to crosslinking density, swelling behavior, and matrix permeability.¹⁶⁸

Across studies, a recurring pattern indicates that antimicrobial efficacy in ANPs is strongly diffusion-dependent. Moderately crosslinked networks with higher swelling ratios tend to facilitate improved EO mobility and enhanced antibacterial activity against *E. coli*, *P. aeruginosa*, and *S. aureus*,¹⁶⁹ whereas highly crosslinked matrices may restrict EO diffusion despite high encapsulation efficiency. These observations demonstrate that structural integrity alone does not ensure therapeutic amplification; instead, optimizing ionic network density is critical for balancing stability with bioactive availability.

Head-to-head comparisons consistently reveal that while alginate nanoparticles improve EO stability and baseline antimicrobial performance, cationic systems such as chitosan nanoparticles frequently achieve lower IC₅₀ values and stronger bactericidal effects.^{83,170} Mechanistically, this difference reflects surface charge: alginate particles typically exhibit neutral or negative zeta potentials, limiting direct electrostatic adhesion to negatively charged bacterial membranes. Consequently, ANP efficacy arises predominantly from controlled diffusion rather than charge-mediated membrane destabilization.

Relative to nanoemulsions, alginate nanoparticles generally display slower initial antimicrobial kinetics but enhanced structural robustness under physiological conditions. Compared with electrospun membranes, ANPs offer better adaptability to moist or mucosal environments but lack intrinsic mechanical reinforcement and barrier functionality. These distinctions suggest that alginate systems may be particularly suited for gentle mucosal delivery or controlled dermal release applications where biocompatibility and sustained exposure are prioritized over rapid bactericidal onset.

Translational considerations further differentiate alginate platforms. Ionic crosslinking is sensitive to pH and ionic strength variations, which may influence particle stability in physiological fluids. Variability in mannuronic/guluronic acid composition can alter mechanical properties and release behavior, complicating batch-to-batch reproducibility. Additionally, precise control of calcium-mediated gelation is required to maintain uniform particle size distribution at scale.



Overall, alginate nanoparticles provide a stability-oriented and biocompatible delivery architecture in which antimicrobial performance is primarily diffusion-driven. Their therapeutic advantage appears context-dependent and may be enhanced through hybridization with cationic polymers, integrating ionic network stability with improved microbial interaction.

6.1.6. Hybrid encapsulation approaches. Hybrid encapsulation systems integrate two or more delivery architectures into hierarchical nanoassemblies, enabling sequential and spatially controlled therapeutic modulation. Unlike single-platform systems in which biological performance is governed by one dominant mechanism (*e.g.*, charge interaction or diffusion control), hybrids combine complementary release pathways—such as nanogel-mediated diffusion embedded within electrospun structural scaffolds—thereby generating multistage kinetic profiles and enhanced mechanical stability.

Across studies, three consistent functional advantages emerge. First, hierarchical release control. Embedding EO-loaded nanogels or nanoemulsions within electrospun fibers reduces premature volatilization while introducing sequential diffusion phases: an initial release from nanoscale droplets followed by sustained liberation governed by the surrounding polymer matrix.^{32,59,171} This layered kinetic behavior appears particularly beneficial in chronic wound environments, where rapid antimicrobial onset must be followed by prolonged anti-inflammatory and regenerative support.

Second, structural–bioactive synergy. Hybrid nanofiber–nanogel constructs leverage the mechanical integrity and breathability of fibrous scaffolds alongside the high loading efficiency and hydration capacity of hydrogel domains.¹⁷² Compared with standalone nanogels, these assemblies improve spatial retention and durability; relative to fibers containing directly blended EO, pre-stabilized nanogel-in-fiber systems exhibit more predictable release profiles and reduced burst effects. Such integration enables simultaneous infection control, moisture balance, and cellular compatibility within a single platform.

Third, molecular-level stabilization through inclusion complexes. Incorporation of cyclodextrin–EO host–guest complexes into nanofibers introduces an additional encapsulation layer that enhances solubility and volatility control.¹⁷³ Unlike electrostatic or diffusion-driven stabilization, inclusion complexes rely on molecular interactions that improve storage stability and homogeneous EO distribution within hydrophilic matrices. However, loading capacity may be lower than in nanoemulsion-based hybrids, potentially limiting maximal antimicrobial intensity.

Hybrid systems have demonstrated strong antimicrobial performance against drug-resistant pathogens and biofilm-associated infections, often achieving near-complete inhibition *in vitro*.^{35,171} Nonetheless, the therapeutic amplification observed in these constructs appears to arise from coordinated modulation of release kinetics, spatial confinement, and matrix reinforcement rather than from additive EO concentration alone.

Despite their multifunctionality, hybrid architectures introduce significant formulation and translational complexity.

Multistep fabrication processes—such as sequential nanoemulsion formation, gelation, and electrospinning—may compromise scalability and increase production cost. Interfacial incompatibility between layers can alter release behavior or mechanical stability over time, while regulatory evaluation becomes more demanding with each added structural component. Consequently, although hybrid systems frequently outperform single-platform designs *in vitro*, their clinical superiority must be validated against manufacturing feasibility and reproducibility constraints.

Overall, hybrid encapsulation strategies represent a hierarchical multi-mechanism approach best suited for complex pathological scenarios—such as chronic infected wounds or multidrug-resistant biofilm environments—where simultaneous structural support and staged antimicrobial exposure are required. Future standardized head-to-head studies are essential to determine whether the added architectural complexity translates into consistent clinical benefit.

6.1.7. Synergistic encapsulation approach. Synergistic encapsulation strategies focus on co-delivering multiple EOs within a single nanoarchitecture to exploit phytochemical complementarity and enhance antimicrobial or antioxidant efficacy. Unlike hybrid structural systems, which combine delivery mechanisms, synergistic formulations primarily integrate chemical diversity within a shared nanocarrier. The enhanced performance observed in such systems may arise from coordinated membrane disruption, intracellular enzyme inhibition, and redox modulation occurring simultaneously at the microbial interface.

Across studies, two reproducible patterns are evident. First, nanoemulsification frequently amplifies synergistic interactions by facilitating co-localized delivery of multiple terpenoids. Reduced droplet size (< 150 nm) increases interfacial area and promotes simultaneous interaction of chemically distinct EO constituents with microbial membranes.^{23,174} Optimized EO ratios have demonstrated pathogen-specific improvements, indicating that synergy is context-dependent rather than universal. Distinct combinations may be required to effectively target *E. coli*, *S. aureus*, *E. faecalis*, or *P. aeruginosa*, reflecting differences in membrane composition and efflux capacity. These findings emphasize that rational blend design must align phytochemical profiles with microbial susceptibility patterns rather than assuming additive broad-spectrum activity.

Second, reported enhancements require careful quantitative validation. Although many blended nanoemulsions exhibit reduced MIC values and increased antioxidant capacity,^{175,176} mechanistic confirmation of true synergy is inconsistently supported by fractional inhibitory concentration indices (FICI) or standardized redox assays. Variability in antioxidant methodologies (*e.g.*, DPPH, ABTS, FRAP) further complicates cross-study comparison. Consequently, some reported improvements may reflect enhanced stability and delivery efficiency rather than verified biochemical synergy.

Overall, synergistic encapsulation represents a chemically driven optimization strategy that leverages nano-scale co-delivery to enhance antimicrobial efficiency at reduced dosages.



However, rigorous interaction analyses and standardized release profiling are necessary to distinguish true synergism from additive or delivery-mediated effects.

6.2. Anti-cancer therapeutics and targeted delivery

In anticancer applications, the therapeutic performance of encapsulated HEOs is primarily governed by intracellular delivery efficiency, tumor microenvironment interaction, and controlled release behavior rather than by cytotoxic potency alone. Although numerous studies report reduced IC₅₀ values and enhanced apoptosis following nanoencapsulation of HEO constituents (Fig. 4), comparative interpretation requires consideration of nanoarchitectural parameters such as particle size distribution, surface charge, polydispersity index, and release kinetics.

6.2.1. Nanoemulsions. EO-based nanoemulsions enhance anticancer activity primarily through droplet-size-dependent modulation of cellular uptake and intracellular release. In oncology applications, nanoscale droplets (<200 nm) increase interfacial surface area, promote clathrin- or caveolae-mediated endocytosis, and facilitate cytoplasmic delivery of hydrophobic terpenoids. Consequently, therapeutic enhancement arises not only from intrinsic EO bioactivity but from architecture-driven improvements in dispersion stability, bioavailability, and tumor-cell interaction.

Across reported studies, nanoemulsions consistently demonstrate lower IC₅₀ values compared with free EOs; however, interpretation requires careful consideration of physicochemical parameters. For example, eugenol-loaded nanoemulsions improved cytotoxicity against MCF-7 cells while maintaining hemocompatibility,⁵¹ and *Mentha piperita* EO nanoemulsions exhibited sustained cytotoxic effects across breast cancer cell lines.²² In both cases, enhanced efficacy correlated with reduced droplet diameter and improved colloidal stability, suggesting that internalization efficiency rather than phytochemical potency alone drives performance. Nevertheless, direct cross-study comparison remains limited because particle size distribution, surfactant composition, and encapsulation efficiency are not consistently standardized.

Similar architecture-dependent enhancement is observed beyond breast cancer models. Nanoemulsified *Mentha arvensis* EO significantly increased apoptosis in anaplastic thyroid carcinoma cells,¹⁵⁹ while α -pinene and 2-carene nanoemulsions demonstrated improved pro-apoptotic activity and reduced IC₅₀ values in melanoma and triple-negative breast cancer models, with partial *in vivo* tumor regression reported for 2-carene systems.^{177,178} Although modulation of BAX/BCL-2 balance and caspase activation is frequently reported, quantitative intracellular accumulation studies are rarely performed. It therefore remains unclear whether apoptosis amplification reflects increased intracellular EO concentration or altered membrane-mitochondrial interactions mediated by nanoarchitecture.

Synergistic strategies further illustrate the delivery advantages of nanoemulsions. A clove-thyme EO nanoemulsion demonstrated stronger cytotoxicity than free oils and taxol in HepG2 and MCF-7 models, associated with caspase activation

and VEGFR-2 inhibition.²³ Likewise, *Teucrium polium* EO nanoemulsions enhanced oxaliplatin sensitivity in colon cancer cells, with measurable synergistic indices.¹⁷⁹ These findings suggest that nanoemulsions may modulate oxidative stress thresholds and membrane permeability, thereby sensitizing tumor cells to chemotherapeutics. However, most synergy assessments are confined to 2D monolayer cultures, and pharmacokinetic validation *in vivo* remains limited.


Importantly, comparative evaluations across delivery architectures indicate context-dependent superiority. For example, *Cuminum cyminum* EO nanogel formulations outperformed corresponding nanoemulsions in certain cancer models due to prolonged release and sustained tumor exposure.¹⁰⁴ This suggests that nanoemulsions may favor rapid intracellular delivery and short-term cytotoxic action, whereas gel-based matrices provide extended exposure. Head-to-head kinetic comparisons under identical tumor conditions are still scarce, preventing definitive architecture ranking.

From a translational perspective, several critical gaps persist. Many studies lack detailed reporting of encapsulation efficiency, droplet stability in serum-containing media, long-term storage behavior, and batch-to-batch reproducibility. Moreover, systemic biodistribution, reticuloendothelial system clearance, immune interaction, and tumor accumulation efficiency are infrequently quantified in animal models. Because clinical nanoemulsions must remain stable under physiological dilution and withstand large-scale manufacturing constraints, scalability of high-energy emulsification techniques and GMP-compliant reproducibility represent major barriers to translation.

Overall, EO-based nanoemulsions constitute a flexible and potent delivery platform capable of enhancing intracellular delivery, apoptosis induction, and chemotherapeutic sensitization. However, therapeutic superiority appears strongly dependent on droplet size control, physicochemical stability, and tumor model context. Rigorous integration of standardized characterization, serum stability testing, pharmacokinetic profiling, and scalable production strategies will be essential to determine whether nanoemulsions can achieve clinically meaningful performance beyond *in vitro* cytotoxicity.

6.2.2. Chitosan nanoparticles. Chitosan nanoparticles (CNPs) represent a charge-driven nanoarchitecture in which electrostatic interaction plays a central role in anticancer delivery. Owing to their intrinsic cationic surface, CNPs promote adhesion to negatively charged tumor cell membranes, facilitate endocytic uptake, and enable diffusion-controlled intracellular release. In contrast to nanoemulsions—where delivery is largely governed by droplet dispersion and passive accumulation—CNP systems combine membrane adhesion, polymer-mediated retention, and sustained release kinetics. Consequently, therapeutic performance depends not only on EO potency but critically on particle size (<200 nm), zeta potential balance, and crosslinking density.

Across diverse EO formulations, CNP encapsulation generally reduces IC₅₀ values and amplifies apoptotic signaling compared with free oils. For instance, *Chelidonium majus*



EO-loaded CNPs decreased IC_{50} values by up to twofold and significantly increased apoptosis in MCF-7 cells,⁵² while green tea EO nanoformulations demonstrated enhanced cytotoxicity in HepG-2, MCF-7, and HCT-116 models, with radiolabeled systems indicating improved tumor accumulation and reduced reticuloendothelial uptake *in vivo*.⁸¹ These observations suggest that surface charge uniformity and nanoscale size distribution influence systemic circulation and tumor localization, although direct comparisons with other nanoarchitectures remain limited.

Multiple monoterpene-rich EOs—including citral-containing *Lippia citriodora*, carvacrol, carvone, limonene, and α -pinene systems—exhibit amplified pro-apoptotic effects following CNP encapsulation.^{180–182} Frequently reported mechanisms include Bax/Bcl-2 modulation, caspase activation, and oxidative-stress-mediated apoptosis. However, quantitative intracellular accumulation studies are rarely conducted. It therefore remains unclear whether apoptosis enhancement primarily reflects increased EO concentration within tumor cells or partial contribution of chitosan-induced membrane destabilization. Real-time release profiling and intracellular concentration mapping would clarify whether CNPs function solely as delivery enhancers or as synergistic bioactive participants.

Comparative studies indicate architecture-dependent differences in performance. In breast cancer models, *Zingiber officinale* EO-loaded CNPs outperformed both free EO and alginate nanoparticles,⁸³ likely due to stronger electrostatic membrane interaction and enhanced intracellular retention rather than encapsulation efficiency alone. Compared with nanoemulsions, CNPs may exhibit slower initial release yet prolonged intracellular persistence, potentially favoring sustained apoptosis signaling over rapid cytotoxic bursts. Nonetheless, systematic head-to-head kinetic comparisons under identical tumor conditions remain scarce, preventing definitive ranking of delivery platforms.

From a translational standpoint, CNP systems face important reproducibility and standardization challenges. Variations in chitosan molecular weight and degree of deacetylation substantially influence particle size distribution, zeta potential, crosslinking efficiency, and drug release kinetics. Such variability complicates batch-to-batch consistency and GMP-compliant scale-up. Furthermore, for systems intended for systemic administration, surface chemistry strictly dictates the nanocarrier's *in vivo* fate through the dynamic formation of a protein corona. Excessive positive surface charge (characteristic of bare cationic polymers like chitosan) selectively recruits negatively charged circulating proteins, particularly opsonins such as fibrinogen, immunoglobulins, and complement factors. This specific opsonization triggers rapid recognition and clearance by the mononuclear phagocyte system (MPS). In contrast, nanocarriers with neutral or sterically hindered surfaces (*e.g.*, *via* PEGylation) effectively minimize electrostatic protein adsorption, conferring a “stealth” effect that prolongs systemic circulation. Crucially, the composition of this protein corona immediately redefines the “biological identity” of the particle, directly impacting the biological

properties of the encapsulated HEOs. A dense corona matrix can physically obstruct the diffusion of volatile monoterpenes, prematurely alter release kinetics, or mask surface-functionalized targeting ligands, thereby reducing the intended antibacterial or antitumoral efficacy of the HEO at the target site.¹⁸³ Comprehensive pharmacokinetic, immunogenicity, and long-term toxicity studies remain limited, restricting accurate evaluation of their clinical feasibility.

Overall, CNP-based EO delivery systems offer mechanistically distinct advantages arising from charge-mediated tumor cell interaction and sustained intracellular release. However, therapeutic superiority appears context-dependent and highly sensitive to surface charge optimization and polymer standardization. Rigorous comparative studies integrating standardized physicochemical characterization, serum stability testing, and *in vivo* biodistribution analyses are necessary to determine whether CNPs consistently outperform nanoemulsion and alginate platforms in systemic anticancer therapy.

6.2.3. Alginate nanoparticles. Alginate nanoparticles (Alg-NPs) function as ionically crosslinked hydrogel matrices in which EO molecules are physically entrapped within a polysaccharide network. In contrast to cationic chitosan nanoparticles that rely on electrostatic membrane adhesion, Alg-NPs typically exhibit neutral to slightly negative surface charge, resulting in limited direct membrane interaction and reduced endocytic uptake. Their anticancer performance therefore appears to depend predominantly on diffusion-controlled, sustained EO release and microenvironment-responsive exposure rather than rapid intracellular internalization.

Across various EO systems, alginate encapsulation generally improves physicochemical stability and prolongs apoptotic signaling compared with free oils. Early studies using eugenol-rich *Syzygium aromaticum* and *Rosmarinus officinalis* formulations demonstrated dose-dependent apoptosis induction in melanoma and breast cancer cells, with activity influenced by EO composition and cancer type.^{184,185} In some cases, α -pinene-loaded Alg-NPs exhibited stronger activity than whole-EO formulations, suggesting that alginate matrices may preferentially stabilize or release specific low-molecular-weight monoterpenes. However, most investigations do not quantify encapsulation efficiency of individual EO fractions, making it difficult to determine whether enhanced efficacy arises from selective component enrichment or from modified release kinetics.

More recent work highlights the relevance of tumor microenvironment conditions. Encapsulation of *Ferula gummosa* EO and β -pinene significantly lowered IC_{50} values in melanoma and triple-negative breast cancer models, with cytotoxicity intensified under hyperoxic conditions.¹⁸⁶ This observation suggests that sustained EO release from Alg-NPs may amplify reactive oxygen species (ROS)-mediated stress when oxygen availability is elevated. Conversely, improved performance under hypoxic conditions reported for citral- or *Cymbopogon citratus*-loaded systems indicates that matrix-controlled release may partially overcome diffusion limitations and metabolic resistance typical of oxygen-deprived tumors.¹⁸⁷ Together, these findings imply that Alg-NPs modulate the temporal dynamics



of oxidative stress rather than directly enhancing cellular uptake.

Mechanistically, Bax/Bcl-2 modulation and mitochondrial dysfunction are frequently reported endpoints, consistent with prolonged EO exposure. Compared with CNP systems, Alg-NPs generally display slower initial cytotoxic onset but more sustained apoptotic activation, aligning with matrix-governed diffusion behavior. Relative to nanoemulsions, alginate carriers may show reduced immediate uptake efficiency yet improved colloidal and chemical stability under physiological conditions. Thus, Alg-NPs appear particularly suited for sustained local therapy or microenvironment-responsive applications rather than rapid systemic cytotoxic intervention.

Despite promising *in vitro* apoptosis data, several translational challenges remain underexplored. Alginate gelation relies on ionic crosslinking—commonly *via* Ca²⁺ bridges—which may destabilize under physiological ion exchange conditions, leading to premature swelling or erosion. Variability in crosslinking density significantly influences particle size, degradation rate, and EO release kinetics, yet these parameters are rarely standardized across studies. Furthermore, serum stability, protein adsorption behavior, large-scale reproducibility of gelation processes, and *in vivo* pharmacokinetics remain insufficiently characterized. Without systematic evaluation of these factors, clinical feasibility cannot be reliably assessed.

Overall, Alg-NPs provide a matrix-driven, diffusion-controlled delivery platform that enhances EO stability and enables temporally sustained apoptosis induction. Their therapeutic impact appears particularly sensitive to tumor oxygenation status and release kinetics. However, optimization of crosslinking stability, quantitative release profiling, and direct head-to-head comparisons with charge-mediated and droplet-based nanoarchitectures are essential to establish whether Alg-NPs offer a consistent translational advantage in systemic oncology applications.

6.2.4. Hydrogels (nanogels). Hydrogel- and nanogel-based systems represent three-dimensional crosslinked polymer networks that entrap EO molecules within hydrated matrices, enabling spatial confinement and diffusion-controlled release. Unlike nanoemulsions (droplet-dispersed carriers) or chitosan nanoparticles (charge-mediated systems), hydrogels primarily function as localized depots in which therapeutic activity is governed by crosslinking density, swelling behavior, and responsiveness to external stimuli such as temperature, pH, or irradiation. Their anticancer performance therefore depends less on rapid intracellular uptake and more on sustained local exposure and stimulus-triggered release dynamics.

A notable advancement is the integration of EO-loaded hydrogels with photothermal therapy (PTT). For example, a carvacrol-loaded marine-derived hydrogel incorporating gold nanobipyramids enabled controlled EO retention while achieving efficient light-to-heat conversion under near-infrared irradiation.⁹⁰ Fractionated PTT combined with carvacrol delivery produced greater tumor ablation than either modality alone, illustrating how hydrogel confinement can synchronize chemotherapeutic and photothermal effects. Mechanistically, activation of apoptotic markers such as pJNK and p53 was

observed; however, quantitative release profiling during irradiation was not systematically reported. As a result, it remains unclear whether enhanced cytotoxicity was primarily temperature-driven, release-mediated, or due to synergistic ROS amplification.

Beyond multimodal systems, EO-loaded nanogels alone improve physicochemical stabilization of volatile constituents and prolong tumor exposure. Encapsulation of *Myrtus communis* EO into nanogels increased cytotoxic potency against melanoma cells compared with the free oil,⁵⁹ while *Mentha pulegium* EO formulations demonstrated differential performance between nanoemulsion and nanogel systems.¹⁸⁸ In these comparisons, nanoemulsions produced stronger immediate cytotoxic effects—likely due to faster uptake and burst release—whereas nanogels induced more gradual apoptotic activation consistent with matrix-regulated diffusion. This kinetic distinction suggests that nanogels may be more suitable for sustained local therapy or implantable applications rather than rapid systemic tumor eradication.


Despite multifunctional potential, hydrogel-based systems present distinct translational constraints. High water content and structural heterogeneity can compromise mechanical robustness and batch reproducibility. Injectable formulations require careful optimization to ensure consistent crosslinking density and predictable degradation profiles. For nanogel systems intended for systemic circulation, avoidance of rapid clearance and maintenance of stable particle size distribution remain challenging. Moreover, large-scale sterilization procedures and long-term storage stability are rarely addressed in preclinical studies.

Collectively, hydrogel and nanogel platforms enable matrix-driven, stimulus-responsive EO delivery with particular relevance for localized or combination cancer therapies. However, their clinical translation will require rigorous standardization of release kinetics, mechanical stability, degradation behavior, and *in vivo* pharmacokinetic profiling.

6.3. Anti-inflammatory and antioxidant applications

6.3.1. Nanoemulsions. Nanoemulsion systems have emerged as versatile and highly effective platforms for enhancing the antioxidant and anti-inflammatory performance of HEOs by improving their physicochemical stability, bioaccessibility, and biological interactions (Fig. 4). Across diverse formulations, EO-loaded nanoemulsions consistently outperform free oils, not only by mitigating oxidative stress but also by modulating inflammatory signaling pathways in both *in vitro* and *in vivo* models.

A key advantage of nanoemulsification lies in stabilizing volatile EO constituents while facilitating their penetration into biological systems. For instance, *Cuminum cyminum* EO nanoemulsions exhibit pronounced antioxidant capacity, illustrating the broader potential of nanoscale dispersion to enhance cellular protection against oxidative insults.¹⁰⁴ Similarly, advanced carrier architectures such as the bovine serum albumin-dextran sulfate conjugate-sodium deoxycholate system for *Alpinia zerumbet* Fructus EO demonstrate how structural tailoring can significantly improve bioavailability and therapeutic efficacy.⁹¹ In diabetic



models, these nanoemulsions protected endothelial cells from high-glucose-induced oxidative damage, restored vascular function, and attenuated inflammatory responses more effectively than the free EO, primarily due to prolonged systemic circulation and improved absorption.

Beyond antioxidant effects, nanoemulsions have shown robust anti-inflammatory activity while maintaining favorable biocompatibility profiles. Formulations containing *Curcuma longa* leaf EO suppressed nitric oxide production in activated macrophages without cytotoxicity.¹⁸⁹ Likewise, carvacrol nanoemulsions exhibited sustained anti-edematogenic activity and reduced IL-1 β levels with dexamethasone-like potency, highlighting the importance of optimized droplet size, low polydispersity, and colloidal stability for achieving controlled and durable therapeutic responses.¹⁹⁰

Interestingly, although crude *Eucalyptus camaldulensis* oil displayed stronger antioxidant activity *in vitro*, its nanoemulsified counterpart produced superior *in vivo* outcomes, including enhanced anti-inflammatory, hepatoprotective, and nephroprotective effects in CCl₄-induced models.⁴² Molecular docking analyses further supported these observations, revealing strong interactions between EO constituents—particularly sesquiterpenes—and key proteins involved in oxidative stress and inflammatory pathways. These findings collectively suggest that nanoemulsification not only enhances delivery but may also amplify mechanistic targeting at the molecular level.

Optimization studies further underscore the flexibility of nanoemulsions as customizable therapeutic platforms. Blended EO nanoemulsions composed of rosemary, sage, and thyme achieved synergistically enhanced antioxidant activity, while eugenol- and 2-carene-loaded nanoemulsions increased endogenous antioxidant enzyme levels, reduced inflammatory markers, and improved tissue integrity *in vivo*.^{51,174,178} Together, these results indicate that both single-EO and multi-EO nanoemulsions can be rationally engineered to maximize therapeutic efficacy through synergistic and formulation-driven effects.

Collectively, current evidence positions EO-based nanoemulsions as powerful platforms for reinforcing antioxidant defenses and attenuating inflammatory responses *via* enhanced stability, improved systemic distribution, and modulation of key molecular pathways. Their consistent efficacy across experimental models underscores their promise as strong candidates for further preclinical and translational development.

6.3.2. Chitosan nanoparticles. Chitosan nanoparticles (CNPs) have emerged as highly effective nanocarriers for HEOs in antioxidant and anti-inflammatory applications due to their intrinsic biocompatibility, mucoadhesiveness, and cationic surface properties. Beyond serving as passive carriers, CNPs actively influence bioactivity by protecting volatile phenolic and terpenoid constituents from premature oxidation while enabling controlled, diffusion-driven release. This stabilization effect underlies the enhanced free-radical scavenging performance observed for *Rosmarinus officinalis* and *Cynometra cauliflora* EO formulations, where nanoencapsulation significantly improved antioxidant capacity compared with free oils.^{30,113} Targeted delivery of dominant active molecules—such as citral

from *Lippia citriodora* EO—further illustrates that chitosan systems can be tailored to maximize the functional contribution of key constituents, sometimes surpassing whole-oil formulations in redox modulation efficiency.¹⁸⁰

Importantly, the benefits of CNPs extend beyond oxidative stabilization to immunomodulatory regulation. In chronic inflammatory models, including arthritis, EO-loaded CNPs significantly attenuated inflammatory progression. For example, geranium EO–CNP formulations reduced joint inflammation, normalized hematological indices, and suppressed major pro-inflammatory cytokines such as IL-6 and TNF- α , accompanied by histological improvement.¹⁹¹ These outcomes suggest that sustained EO release, combined with enhanced tissue interaction mediated by the cationic chitosan surface, contributes to prolonged therapeutic exposure and more effective cytokine modulation.

CNPs also facilitate synergistic anti-inflammatory strategies. A ternary nanoformulation combining bee pollen extract and thymol oil demonstrated pronounced anti-inflammatory and antiproliferative effects in cancer models, activating intrinsic apoptotic pathways *via* caspase-3, caspase-9, and p53 upregulation.¹⁹² Similarly, carvone-loaded CNPs significantly reduced arthritic severity and downregulated multiple pro-inflammatory mediators (TNF- α , IL-1 β , IL-17A, IL-33), while simultaneously increasing anti-inflammatory cytokines such as IL-4 and IL-10.¹⁹³ The concurrent modulation of both pro- and anti-inflammatory signals indicates that CNP systems may promote a shift toward immune homeostasis rather than simple cytokine suppression.

Mechanistically, the enhanced bioactivity of EO-loaded CNPs likely arises from a combination of factors: improved chemical stability, increased mucosal and cellular interaction due to positive surface charge, and sustained release kinetics that extend the therapeutic window. However, the relative contribution of chitosan's intrinsic immunomodulatory properties *versus* EO-mediated effects is rarely quantified, representing an important area for further investigation.

Overall, chitosan nanoencapsulation strengthens both antioxidant defense and inflammatory regulation through architecture-dependent stabilization and immune-interactive delivery. These properties position CNP-based EO formulations as promising candidates for managing oxidative stress-associated disorders, chronic inflammatory diseases, and inflammation-driven oncological conditions, provided that polymer characteristics and immune compatibility are carefully optimized.

6.3.3. Hydrogels (nanogels). Hydrogel and nanogel systems represent structurally distinct delivery platforms that enhance the anti-inflammatory and antioxidant performance of HEOs through spatial confinement, high hydration capacity, and diffusion-controlled release. Unlike droplet-based nanoemulsions or charge-mediated chitosan nanoparticles, hydrogels primarily function as localized depots, maintaining prolonged residence time at the application site while minimizing systemic dispersion. This architectural feature makes them particularly suitable for topical and tissue-repair-oriented therapies.



Encapsulation within hydrogel matrices stabilizes volatile EO constituents and sustains their bioactivity under inflammatory conditions. Thermosensitive nanogels containing *Pectis brevipedunculata* EO demonstrated rapid edema suppression *in vivo*, suggesting that matrix-regulated release can efficiently modulate acute inflammatory responses even in infection-associated settings.¹⁰⁵ Similarly, thymol–chitosan hydrogel formulations showed dose-dependent anti-inflammatory effects and promoted epithelial and collagen regeneration over extended treatment periods.¹⁶² These findings highlight the importance of formulation balance, as excessive EO loading may increase irritation risk, whereas optimized concentrations enable sustained therapeutic benefit.

Polyelectrolyte complex-based nanogels further illustrate the multifunctional potential of hydrogel architectures. Systems incorporating caffeic acid and eugenol within curdlan-, glucomannan-, chitosan-, or lactoferrin-based networks achieved prolonged stability and controlled release for up to 72 h.³¹ Enhanced antioxidant and antibacterial performance, along with reduced IC₅₀ values in colorectal cancer models, indicate that such hybrid nanogels can simultaneously engage redox regulation, antimicrobial defense, and cell-signaling modulation. These effects likely arise from sustained local exposure combined with protection of phenolic constituents against premature degradation.

Improved radical-scavenging activity has also been reported for hydrogels containing *Mentha spicata* and *Myrtus communis* EOs, where nanoencapsulation increased antioxidant efficiency compared with bulk oils.^{59,172} In topical applications, nanoemulsion-based gels (nanoemulgels) containing oregano EO further demonstrate how combining droplet-mediated penetration with gel-mediated retention can enhance anti-inflammatory and wound-healing outcomes.³² Reduced inflammatory cell infiltration and improved tissue remodeling observed in these systems suggest that prolonged redox stabilization contributes to a more favorable regenerative microenvironment.

Despite these advantages, hydrogel-based EO systems must address practical considerations such as viscosity optimization, long-term physicochemical stability, reproducibility of cross-linking density, and maintenance of skin compatibility during extended application. Careful balancing of release kinetics and dermal tolerance remains critical for successful translation.

Overall, EO-loaded hydrogels and nanogels provide localized, diffusion-governed platforms capable of reinforcing antioxidant defenses and modulating inflammatory cascades while supporting tissue repair. Their architecture-driven capacity for sustained exposure and multifunctional integration positions them as valuable candidates for dermatological and regenerative applications, particularly where prolonged local activity is required.

6.3.4. Electrospinning. Electrospinning represents a structurally distinct strategy for incorporating HEOs into nanofibrous matrices, enabling enhanced stability, high surface-area exposure, and controlled release within solid scaffolds. The ultrafine fiber architecture provides extensive interfacial contact between EO molecules and the surrounding environment, which can intensify antioxidant activity while maintaining

localized retention. Unlike colloidal carriers, electrospun systems primarily function as surface-deployable membranes or dressings, making them particularly suitable for wound healing and regenerative applications.

Compatibility with molecular encapsulation approaches—such as cyclodextrin inclusion complexation—further strengthens electrospun platforms. Incorporation of EO–cyclodextrin complexes into nanofibers has been shown to improve hydrophilicity, moisture retention, and dermal compatibility, properties essential for cosmetic and dermatological use.¹⁹⁴ In biodegradable polymer systems such as polylactic acid, EO incorporation into electrospun matrices enhanced antioxidant performance relative to conventional synthetic antioxidants, likely due to uniform molecular dispersion and increased surface availability within the fibrous network.⁹⁶ Functional activity was influenced by both EO loading and fiber morphology, indicating that antioxidant performance is architecture-dependent rather than solely composition-driven.

Electrospun membranes can also be engineered for multifunctionality. Co-delivery of EOs with complementary bioactive compounds, such as lecithin within poly(lactic-*co*-glycolic acid) fibers, produced combined antimicrobial, antioxidant, and anti-inflammatory effects that exceeded simple additive interactions.¹⁹⁵ Mechanistically, these systems modulated key redox and inflammatory pathways, including activation of Nrf2 signaling and suppression of NF- κ B activity. *In vivo*, such regulation translated into reduced collagen overproduction and attenuation of fibroblast-to-myofibroblast transition, thereby limiting postoperative tissue adhesion. These findings highlight the ability of electrospun EO systems to shape local inflammatory microenvironments while supporting regenerative remodeling.

Despite these advantages, electrospinning-based EO delivery must address challenges related to scalability, solvent residues, fiber reproducibility, and long-term storage stability. Furthermore, release kinetics can be highly sensitive to polymer degradation rate and environmental humidity, necessitating standardized characterization for clinical translation. Overall, electrospun nanofibrous systems provide architecture-driven stabilization and localized bioactivity enhancement of EOs, particularly in topical and tissue-regenerative contexts where sustained surface exposure is desirable.

Across antimicrobial, anticancer, and anti-inflammatory applications, polymer-encapsulated HEO systems consistently demonstrate that therapeutic performance is governed less by nanoscale reduction alone and more by carrier architecture, surface functionality, and release kinetics. Colloidal systems emphasize rapid membrane interaction and systemic dispersion; charge-modulated nanoparticles influence cellular internalization and biofilm disruption; hydrogel-based matrices enable localized, diffusion-controlled exposure; and scaffold-like constructs integrate mechanical support with sustained surface bioactivity. While encapsulation generally enhances stability and efficacy relative to free oils, cross-platform superiority remains context-dependent and insufficiently standardized. Systematic comparison incorporating physicochemical characterization,



mechanistic uptake studies, and *in vivo* pharmacokinetic profiling is required to determine which architectures offer reproducible advantages under clinically relevant conditions.

Table 5 integrates the principal polymer-based nanoencapsulation systems discussed in Section 6, correlating carrier architecture with physicochemical attributes, bioefficacy trends, scalability constraints, and translational limitations. The comparative analysis underscores that architecture-dependent performance cannot be generalized without standardized *in vivo* validation, pharmacokinetic profiling, and reproducible fabrication methodologies. Future research must therefore align mechanistic evaluation with scalable manufacturing strategies to enable clinically viable HEO-based formulations.

7. Biosafety, toxicity profiles, and regulatory considerations

While nanoencapsulation may reduce the apparent acute toxicity of free HEOs under certain conditions, generalized claims regarding their “absolute safety” are not scientifically justified. The safety profile of nanoencapsulated bioactive systems depends on dose, exposure duration, release kinetics, carrier composition, and biodistribution behavior.^{197–200} Accordingly, comprehensive evaluation of dose-dependent cytotoxicity, *in vivo* accumulation, immunogenicity, and long-term exposure effects remains essential for responsible translational development.

7.1. Terpenoid reactivity, monoterpene toxicity, and oxidative by-products

HEOs are chemically complex mixtures dominated by monoterpenes and phenolic constituents with inherent reactivity. Although many components are classified as generally recognized as safe (GRAS) at low concentrations, toxicological evidence demonstrates that excessive dosing or prolonged exposure may result in hepatotoxicity, nephrotoxicity, neurotoxicity, and hypersensitivity reactions.^{201–203}

Volatile terpenoids such as limonene and linalool are particularly susceptible to autoxidation under improper storage or oxidative stress, forming hydroperoxides and epoxides with increased sensitizing and cytotoxic potential.²⁰² Encapsulation within polymeric matrices may reduce premature oxidation and limit peak exposure; however, inadequately controlled release profiles can still generate localized high concentrations.

Importantly, reductions in observed cytotoxicity in nanoformulated systems typically reflect modulation of exposure kinetics rather than chemical detoxification of reactive phytoconstituents. Therefore, defining concentration–response relationships, maximum tolerated doses, and therapeutic indices is critical to delineate pharmacologically beneficial ranges from toxicological thresholds.

7.2. Carrier-induced toxicity and polymer degradation

The biosafety of nanoencapsulated HEO systems is co-determined by carrier chemistry, residual processing agents, and degradation behavior.

Natural polymers such as chitosan are generally regarded as biocompatible and degrade into low-molecular-weight oligosaccharides.²⁰⁴ Nevertheless, the use of synthetic cross-linkers (*e.g.*, glutaraldehyde) or certain copolymers may introduce cytotoxic residues if purification is incomplete. Thus, carrier safety cannot be inferred solely from polymer class but must be validated at the formulation level.

The rate of polymer breakdown relative to biological clearance pathways critically influences safety. Particles that degrade slowly may accumulate in tissues, potentially provoking localized inflammatory responses or interfering with cellular homeostasis.²⁰⁵ Conversely, excessively rapid degradation may cause burst release of both bioactives and degradation by-products, altering local microenvironmental conditions.

For example, poly(lactic-*co*-glycolic acid) (PLGA) systems degrade into lactic and glycolic acid derivatives, metabolites generally considered biocompatible; however, lactate has been shown to modulate inflammatory signaling under certain physiological contexts.¹³¹ Degradation behavior is strongly dependent on molecular weight and copolymer ratio: lower-molecular-weight PLGA degrades more rapidly, whereas higher-molecular-weight systems may persist longer and, in some models, induce transient inflammatory responses prior to complete clearance.¹³¹

Despite encouraging short-term biocompatibility findings, systematic long-term *in vivo* studies addressing biodistribution, clearance mechanisms, and potential immunogenicity of nanoencapsulated HEO systems remain limited. Standardized chronic toxicity assessments and pharmacokinetic profiling are therefore essential to establish clinically relevant safety margins.

8. Critical challenges and future perspectives

Despite substantial advances in polymer-based nanoencapsulation systems for HEOs, significant translational barriers continue to limit their progression from laboratory research to clinical and industrial implementation. While biosafety and *in vivo* toxicity considerations (Section 7) define the scientific feasibility of these systems, successful commercialization additionally depends on manufacturing scalability, compositional standardization, and regulatory clarity.

8.1. Translational challenges: standardization, scalability, and regulatory pathways

A primary challenge in botanical nanomedicine arises from the intrinsic chemotype variability of HEOs. Variations in plant genotype, geographic origin, seasonal conditions, and extraction methodology can substantially alter terpene composition, resulting in batch-to-batch inconsistency and unpredictable encapsulation performance.²⁰⁶ Such variability directly affects physicochemical stability, release kinetics, and biological efficacy. Therefore, rigorous chemotyping and gas chromatography–mass spectrometry (GC–MS) fingerprinting should be





Table 5 Comparative overview of polymer-based nanoencapsulation systems for biomedical applications of essential oils

Delivery platform	Representative polymers	Typical biomedical applications	Key physicochemical features	Bioefficacy highlights	Scalability potential	Advantages	Limitations	Ref.
Nanoemulsions	Tween-based systems; BSA-DS-SD complexes; mixed surfactant systems	Anticancer; anti-inflammatory; antioxidant; antimicrobial; hepatoprotective and nephroprotective	Droplet size ~50–200 nm; low PDI; enhanced solubility; improved systemic circulation	Enhanced cytotoxicity vs. free EO; reduced IL-1 β and TNF- α ; improved antioxidant enzyme activity; endothelial protection in diabetic models; enhanced antimicrobial efficacy <i>via</i> improved membrane penetration	High (industrial homogenization feasible)	Improved bioavailability; suitable for systemic delivery; tunable formulation	Potential long-term instability; rapid clearance; limited active targeting	42, 51, 91 and 104
Chitosan nanoparticles (CNPs)	Chitosan-TPP ionic gelation systems; modified chitosan carriers	Anticancer; anti-inflammatory (arthritis); oxidative stress-related disorders; antimicrobial; wound healing	Positive surface charge; mucoadhesive; controlled Fickian diffusion release	Suppression of TNF- α , IL-6, IL-1 β , IL-17A; activation of caspase-3, caspase-9, p53; enhanced ROS-mediated apoptosis in cancer cells; strong antibacterial activity due to electrostatic membrane interaction	Moderate (pH sensitivity; batch variability)	Immunomodulatory; sustained release; enhanced membrane interaction	pH-dependent stability; aggregation risk; scale-up and reproducibility issues	113, 180, 191 and 193
Alginate-based nanoparticles	Sodium alginate; ionically cross-linked alginate systems	Anticancer; antioxidant; antimicrobial	Mild encapsulation conditions; biocompatible matrix; relatively low surface charge	Enhanced cytotoxicity vs. free EO; induction of apoptosis in tumor cells; increased intracellular ROS generation; improved stability of volatile components; antibacterial activity in encapsulated systems	Moderate to high (simple gelation adaptable to scale)	Gentle processing; non-toxic; stable encapsulation	Lower cellular uptake unless surface-modified; limited intrinsic targeting	184, 185, 187 and 196
Hydrogels/nanogels	Chitosan-based hydrogels; curdlan-, glucomannan-, lactoferrin-based networks; thermosensitive systems	Topical anti-inflammatory; wound healing; regenerative therapy; antimicrobial	High water content; sustained release (up to 72 h); enhanced dermal retention	Reduced edema; enhanced re-epithelialization; decreased IC ₅₀ in colorectal cancer cells; improved antioxidant capacity; sustained antibacterial activity in wound models	Moderate (sterilization/storage optimization required)	Excellent for localized therapy; prolonged residence; regenerative support	Limited systemic applicability; diffusion constraints	31, 32, 59 and 162
Electrospun nanofibers	PLA; PLGA; biodegradable polymer blends; polymer/cyclodextrin inclusion complexes	Wound healing; anti-adhesion barriers; regenerative membranes; antimicrobial; antioxidant; anti-inflammatory	High surface-area-to-volume ratio; extracellular matrix-mimicking fibrous structure; controlled diffusion	Nrf2 activation; NF- κ B suppression; reduced fibrosis; enhanced antimicrobial efficacy; improved oxidative stress modulation	Moderate (industrial electrospinning possible; solvent considerations)	Structural support + bioactivity; suitable for regenerative medicine	Solvent residue concerns; loading uniformity challenges; regulatory complexity	96, 194 and 195

implemented as mandatory pre-encapsulation quality control measures. Establishing quantitative acceptance ranges for dominant bioactive constituents is essential to ensure reproducibility and facilitate regulatory evaluation.

Manufacturing scalability presents an additional constraint. Many bench-scale encapsulation techniques rely on tightly controlled laboratory parameters, solvent systems, and mixing dynamics that do not directly translate to industrial production. For example, scale-up of batch solvent evaporation methods frequently alters hydrodynamic conditions, leading to increased particle size and broader polydispersity distributions. Continuous-flow technologies, including microfluidic nanoprecipitation platforms, offer improved reproducibility and tighter control over particle size distribution under optimized conditions.²⁰⁷ Similarly, industrial roll-to-roll electrospinning provides a potentially scalable route for producing EO-loaded nanofibrous membranes for wound care applications. However, solvent management, volatile terpene retention, and long-term storage stability remain critical technical barriers. Economic feasibility must also be considered, as high-purity polymers and standardized, pharmaceutically graded HEOs may substantially increase production costs.

Regulatory classification further complicates translation. Agencies such as the FDA and EMA require comprehensive physicochemical characterization, including particle size distribution, surface chemistry, degradation pathways, and stability profiles. A central regulatory ambiguity concerns product classification. Nano-functionalized matrices that primarily exert physical barrier functions may qualify as medical devices, potentially following streamlined approval pathways such as 510(k) clearance in the United States.^{208,209} In contrast, systems whose therapeutic effect depends on the pharmacological activity of encapsulated HEO constituents are generally classified as drugs or combination products, requiring more extensive preclinical evaluation, clinical trials, and dual GMP compliance. The absence of harmonized regulatory frameworks specific to botanical nanotherapeutics further complicates approval processes.^{210,211}

Finally, oxidative stability during storage remains a persistent concern. Volatile terpenoids are prone to compositional drift over time, potentially altering both efficacy and safety profiles. Standardized stability testing protocols and validated *in vitro*–*in vivo* correlation models are therefore critical components of future development strategies.

8.2. Emerging materials innovations and smart systems

Future development of HEO delivery platforms is expected to move beyond passive encapsulation toward systems capable of controlled, environment-responsive behavior. Advancing from simple protective carriers to programmable architectures may enhance therapeutic precision; however, these concepts remain largely at the experimental stage and require rigorous validation prior to clinical translation.

8.2.1. Smart, stimuli-responsive, and tumor-targeted nano-systems. Stimuli-responsive nanosystems represent a potential strategy for modulating EO release in response to localized

physiological cues such as pH variation, enzymatic activity, temperature, or mechanical stress. Such responsiveness may be particularly relevant in disease-specific microenvironments, including inflamed tissues, infected wounds, or tumors, where biochemical conditions differ from healthy tissue.

Incorporating active targeting mechanisms may further improve site specificity. Surface functionalization with peptides, aptamers, or antibodies could facilitate receptor-mediated uptake by defined cell populations, potentially enhancing intracellular delivery while reducing systemic exposure. Nevertheless, ligand functionalization introduces additional complexity in manufacturing, stability testing, and regulatory evaluation. Consequently, future research must balance targeting precision with translational feasibility.

8.2.2. Layered hybrid assemblies. To address the intrinsic volatility and rapid diffusion of monoterpenes, hybrid architectures combining polymeric matrices with inorganic nanostructures have been proposed. Materials such as mesoporous silica, metal–organic frameworks (MOFs), or layered double hydroxides may provide structural rigidity and improved encapsulation efficiency, potentially limiting terpene evaporation during storage.^{212–214} Core–shell or multilayered assemblies could physically restrict diffusion while allowing controlled degradation of the polymeric component in biological environments.

However, integration of inorganic nanomaterials introduces additional considerations regarding long-term biodegradability, clearance, and regulatory acceptability. Comprehensive toxicological and biodistribution studies will therefore be essential before such hybrid systems can be considered clinically viable.

8.2.3. Integration with 3D-printed biomedical constructs. The convergence of HEO nanoencapsulation with additive manufacturing technologies offers opportunities for localized and structurally customized therapeutic platforms. Incorporation of EO-loaded nanoparticles into bio-inks may enable fabrication of 3D-printed scaffolds or wound dressings capable of sustained antimicrobial or regenerative activity.

Despite this potential, significant technical challenges remain. Volatile EO components may be susceptible to degradation during high-shear mixing or thermal processing steps associated with certain 3D-printing techniques. Additionally, ensuring homogeneous nanoparticle distribution within printed constructs and preserving mechanical integrity are critical for functional reliability. Validation in clinically relevant disease models will be required to substantiate the therapeutic advantages of such integrated systems.

8.2.4. AI-assisted formulation design and standardization. The increasing availability of computational modeling and machine learning tools provides opportunities for data-driven optimization of EO nanoformulations. Predictive algorithms may assist in identifying suitable polymer–EO combinations, simulating release kinetics, and forecasting stability profiles prior to experimental synthesis.^{215–217} Chemometric analysis of GC–MS fingerprints could further support quality standardization by correlating compositional patterns with biological performance.^{218–220}



Nonetheless, the predictive reliability of such models is currently constrained by the scarcity of standardized, high-quality datasets and the intrinsic chemical variability of botanical extracts. At the current state of the art, most machine learning models in this field are limited to evaluating single-component markers (*e.g.*, carvacrol or thymol) or simplified binary mixtures. Capturing the complex, non-linear, and synergistic interactions among the > 50 minor constituents present in whole botanicals remains a profound computational challenge. While advanced deep learning architectures have the theoretical capacity to model these high-dimensional, non-linear “entourage effects,” their practical execution is heavily bottlenecked by the lack of comprehensive multi-component datasets. Future progress will depend on integrating high-throughput computational screening with systematically designed experimental validation studies to bridge the gap between single-marker modeling and full-spectrum translational robustness.

9. Conclusion

HEOs possess broad biological activity, yet their therapeutic application has historically been constrained by volatility, chemical instability, limited aqueous solubility, rapid degradation, and compositional variability. The evidence synthesized in this review indicates that polymer-based nanoencapsulation can effectively mitigate many of these limitations by improving physicochemical stability, modulating release kinetics, and enhancing local or systemic bioavailability.

Across diverse delivery architectures—including polymeric nanoparticles, nanoemulsions, nanogels, electrospun fibers, and hybrid assemblies—encapsulation consistently alters the exposure profile of HEOs, thereby enhancing therapeutic indices relative to free oils. Importantly, performance is not uniform across platforms; rather, biological outcomes are strongly architecture-dependent. Colloidal systems favor systemic dispersion and rapid cellular interaction, hydrogel-based matrices enable localized and diffusion-controlled delivery, and nanofibrous scaffolds provide surface-confined, regenerative functionality. This structure–function relationship underscores that rational carrier selection is central to optimizing therapeutic performance.

Despite these advances, substantial translational barriers remain. Long-term *in vivo* fate, biodistribution, and chronic safety data are limited, particularly for complex or hybrid systems. Botanical chemotype variability complicates standardization and regulatory evaluation, while manufacturing scalability and GMP compliance continue to challenge industrial implementation. Addressing these issues will require coordinated integration of rigorous chemotyping, standardized stability testing, scalable fabrication technologies, and systematically designed pharmacokinetic studies.

Future progress will depend less on the discovery of new essential oils and more on the refinement of delivery architecture, standardization strategies, and translational validation

frameworks. Through disciplined formulation design and evidence-based regulatory alignment, polymer-encapsulated HEO systems may advance from experimental constructs toward clinically reliable therapeutic platforms.

Author contributions

Hamid Rajabi: conceptualization, methodology, investigation, writing – original draft preparation. Utcharaporn Kamsrijai, Narudol Teerapattarakon, Sulukkana Noiprasert, Huang Zhaoxian, Marc Pignitter: writing – review and editing, Saroat Rawdkuen: conceptualization, resources, visualization, writing – review and editing, supervision, project administration.

Conflicts of interest

The authors declare no conflicts of interest.

Data availability

No primary research results, software or code have been included and no new data were generated or analysed as part of this review.

Acknowledgements

This research was funded by Mae Fah Luang University, grant number 01/2026 under the Post-doctoral Fellowship to Dr Hamid Rajabi, the Fundamental Fund: Basic Research [FRB690059/0187] and the Reinventing University Program Fund [F01-683R-04-045], The Office of the Permanent Secretary of the Ministry of Higher Education, Science, Research and Innovation. This project was also funded by National Research Council of Thailand (NRCT-N42A690538).

References

- 1 N. Nasim, I. S. Sandeep and S. Mohanty, Plant-derived natural products for drug discovery: current approaches and prospects, *Nucleus*, 2022, **65**(3), 399–411.
- 2 U. M. G. Bolgen, S. D. Kayiran, Y. Ozogul and F. Ozogul, Essential oil-based nanoemulsions with current knowledge: Formulation, characterization, and applications in food and pharmaceuticals, *Ind. Crops Prod.*, 2025, **233**, 121411.
- 3 R. Kant and A. Kumar, Review on essential oil extraction from aromatic and medicinal plants: Techniques, performance and economic analysis, *Sustainable Chem. Pharm.*, 2022, **30**, 100829.
- 4 S. Naz, S. Javaid, S. U. Rehman and H. Razzaq, Recent advances in polymer nanoencapsulation of essential oils for multi-functional textile finishing, *Mater. Adv.*, 2025, **6**, 2460–2476.
- 5 M. Bunse, R. Daniels, C. Gründemann, J. Heilmann, D. R. Kammerer and M. Keusgen, *et al.*, Essential oils as



- multicomponent mixtures and their potential for human health and well-being, *Front. Pharmacol.*, 2022, **13**, 956541.
- 6 S. Causil and A. L. Villa, Circular Economy and Life Cycle Assessment in Extraction Process and Transformation of Essential Oils for Reaching Sustainable Development Goals, *The Contribution of Life Cycle Analyses and Circular Economy to the Sustainable Development Goals*, Springer, 2025, pp. 3–24.
 - 7 A. Herman and A. P. Herman, Essential oils and their constituents as skin penetration enhancer for transdermal drug delivery: a review, *J. Pharm. Pharmacol.*, 2015, **67**(4), 473–485.
 - 8 F. Z. Benomari, M. Sarazin, D. Chaib, A. Pichette, H. Boumghar and Y. Boumghar, *et al.*, Chemical variability and chemotype concept of essential oils from Algerian wild plants, *Molecules*, 2023, **28**(11), 4439.
 - 9 S. M. dos Santos, C. A. L. Cardoso, P. C. de Oliveira Junior, M. E. da Silva, Z. V. Pereira and R. M. M. F. Silva, *et al.*, Seasonal and geographical variation in the chemical composition of essential oil from *Allophylus edulis* leaves, *S. Afr. J. Bot.*, 2023, **154**, 41–45.
 - 10 S. Sedaghati, H. Rajabi and J. Ahmadi, Fortification of dark chocolate with co-encapsulated saffron extract and caffeine, *Appl. Food Res.*, 2025, 101358.
 - 11 H. Rajabi, S. Sedaghati, H. Farajnezhad and S. M. Jafari, Spray drying of saffron extract-loaded coacervates by carboxymethyl cellulose/maltodextrin/saffron petal anthocyanins, *Carbohydr. Polym. Technol. Appl.*, 2025, 100690.
 - 12 Y. Zhu, Z. Wang, L. Bai, J. Deng and Q. Zhou, Biomaterial-based encapsulated probiotics for biomedical applications: Current status and future perspectives, *Mater. Des.*, 2021, **210**, 110018.
 - 13 S. Yousefi, W. Weisany, S. E. Hosseini and M. Ghasemlou, Mechanisms of nanoencapsulation to boost the antimicrobial efficacy of essential oils: A review, *Food Hydrocolloids*, 2024, **150**, 109655.
 - 14 H. Rajabi, M. Ghorbani, S. M. Jafari, A. S. Mahoonak and G. Rajabzadeh, Retention of saffron bioactive components by spray drying encapsulation using maltodextrin, gum Arabic and gelatin as wall materials, *Food Hydrocolloids*, 2015, **51**, 327–337.
 - 15 H. Rajabi, W. Zhang, Y. H. Jung and S. Rawdkuen, Encapsulation of Anthocyanin for Sustainable Food Packaging: Sources, Preparation, Mechanical, Functional and Physicochemical Properties, *Trends Food Sci. Technol.*, 2026, 105605.
 - 16 H. Rajabi and S. Sedaghati, Advancing sustainable diets through encapsulation and co-encapsulation of bioactive compounds from agricultural by-products: An updated review, *Food Chem. Adv.*, 2026, **11**, 101285.
 - 17 K. Valachová, M. E. Hassan, T. M. Tamer and L. Šoltés, Progress in Hyaluronan-Based Nanoencapsulation Systems for Smart Drug Release and Medical Applications, *Molecules*, 2025, **30**(19), 3883.
 - 18 D. Encinas-Basurto, B. B. Eedara and H. M. Mansour, Biocompatible biodegradable polymeric nanocarriers in dry powder inhalers (DPIs) for pulmonary inhalation delivery, *J. Pharm. Invest.*, 2024, **54**(2), 145–160.
 - 19 R. Abedi-Firoozjah, B. Bahramian, M. Tavassoli, S. Ghaderi, M. Majlesi and N. Ahmadi, *et al.*, Innovative Applications of Polycaprolactone as a Biodegradable Polymer for Food Packaging Films: A Comprehensive Review, *Food Bioprocess Technol.*, 2025, 1–41.
 - 20 W. E. Soliman, N. S. Younis, S. K. Mostafa, M. E. Mohamed, S. M. El-Masry and M. M. Bekhit, *et al.*, A novel antibacterial approach: targeting methicillin-resistant *Staphylococcus aureus* with carvone nanoemulgel, *Appl. Microbiol. Biotechnol.*, 2025, **109**(1), 1–18.
 - 21 R. Essid, A. Ayed, K. Djebali, H. Saad, M. Srasra and Y. Othmani, *et al.*, Anti-candida and anti-leishmanial activities of encapsulated *Cinnamomum verum* essential oil in chitosan nanoparticles, *Molecules*, 2023, **28**(15), 5681.
 - 22 N. Abedinpour, A. Ghanbariasad, A. Taghinezhad and M. Osanloo, Preparation of nanoemulsions of mentha piperita essential oil and investigation of their cytotoxic effect on human breast cancer lines, *Bionanoscience*, 2021, **11**(2), 428–436.
 - 23 A. H. Hashem, A. S. Doghish, A. Ismail, M. M. Hassanin, M. K. Okla and I. A. Saleh, *et al.*, A novel nanoemulsion based on clove and thyme essential oils: Characterization, antibacterial, antibiofilm and anticancer activities, *Electron. J. Biotechnol.*, 2024, **68**, 20–30.
 - 24 H. A. Mohammed, G. M. Sulaiman, R. A. Khan, A. Z. Al-Saffar, M. H. Mohsin and S. Albukhaty, *et al.*, Essential oils pharmacological activity: Chemical markers, biogenesis, plant sources, and commercial products, *Process Biochem.*, 2024, **144**, 112–132.
 - 25 C. Franz and J. Novak, Sources of essential oils, *Handbook of essential oils*, CRC Press, 2020, pp. 41–83.
 - 26 I. N. Gostin and C. F. Blidar, Glandular trichomes and essential oils variability in species of the genus *Phlomis* L.: A Review, *Plants*, 2024, **13**(10), 1338.
 - 27 U. Hazarika, H. F. Mekhatria, J. T. Szabó and B. Gosztola, Effect of lyophilization on the essential oil content and composition of herbs and spices with different volatile secretory structures, *LWT*, 2025, 118188.
 - 28 M. Zuzarte and L. Salgueiro, Essential oils chemistry, *Bioactive essential oils and cancer*, Springer, 2015, pp. 19–61.
 - 29 F. A. N. Fernandes, D. L. H. Maia, K. M. Canuto and E. S. de Brito, Aroma Modulation of Limonene-rich Essential Oil Using Cold Plasma Technology, *Plasma Chem. Plasma Process.*, 2025, 1–20.
 - 30 M. Komijani, H. Rostami, K. Parastouei and M. Fathi, Fabrication, characterization, and effectiveness of *Rosmarinus officinalis* L. essential oil nanoencapsulated by chitosan against *Aspergillus flavus* and *Aspergillus parasiticus* in vitro, *LWT*, 2025, 117799.
 - 31 M. Rofeal, F. Abdelmalek, J. Pietrasik and A. Steinbüchel, A comparative study between two carboxymethylated



- polysaccharides/protein electrostatic and cross-linked nanogels constructed for caffeic acid and eugenol delivery, *Int. J. Biol. Macromol.*, 2023, **245**, 125585.
- 32 S. A. Razack, Y. Lee, H. Shin, S. Duraiarasan, B.-S. Chun and H. W. Kang, Cellulose nanofibrils reinforced chitosan-gelatin based hydrogel loaded with nanoemulsion of oregano essential oil for diabetic wound healing assisted by low level laser therapy, *Int. J. Biol. Macromol.*, 2023, **226**, 220–239.
- 33 W. Wang, X. Yi, R. Zhou, W. Peng, J. Huang and J. Chen, *et al.*, Tea tree oil nanoemulsion targets AgrA protein potentiates amoxicillin efficacy against methicillin-resistant *Staphylococcus aureus*, *Int. J. Biol. Macromol.*, 2025, **292**, 139111.
- 34 W. Weisany, S. P. Soufiania, J. Razmi and A. H. Eshaghadadi, Nano-encapsulation of fenugreek and coriander essential oils using copper oxide NPs: Novel approach for augmenting their effectiveness against *Colletotrichum nymphaeae*, *Ind. Crops Prod.*, 2024, **219**, 119051.
- 35 H. Qasemi, Z. Fereidouni, J. Karimi, A. Abdollahi, E. Zarenezhad and F. Rasti, *et al.*, Promising antibacterial effect of impregnated nanofiber mats with a green nanogel against clinical and standard strains of *Pseudomonas aeruginosa* and *Staphylococcus aureus*, *J. Drug Delivery Sci. Technol.*, 2021, **66**, 102844.
- 36 Q. Peng, F. Wen, X. Tang, S. Lu, H. Li and C. Wang, *et al.*, Carboxymethyl chitosan-gelatin based films filled with whey protein-stabilized nanoscale essential oil for skin wound healing: In vivo and in vitro studies, *Int. J. Biol. Macromol.*, 2025, **305**, 141119.
- 37 M. Cai, Y. Wang, R. Wang, M. Li, W. Zhang and J. Yu, *et al.*, Antibacterial and antibiofilm activities of chitosan nanoparticles loaded with *Ocimum basilicum* L. essential oil, *Int. J. Biol. Macromol.*, 2022, **202**, 122–129.
- 38 B. Pavlič, N. Teslić, G. Zengin, S. Đurović, D. Rakić and A. Cvetanović, *et al.*, Antioxidant and enzyme-inhibitory activity of peppermint extracts and essential oils obtained by conventional and emerging extraction techniques, *Food Chem.*, 2021, **338**, 127724.
- 39 F. Hosseini, M. A. Miri, M. Najafi, S. Soleimanifard and M. Aran, Encapsulation of rosemary essential oil in zein by electrospinning technique, *J. Food Sci.*, 2021, **86**(9), 4070–4086.
- 40 A. O. Manaa, H. H. Baghdadi, N. A. El-Nikhely, L. A. Heikal and L. S. El-Hosseiny, Oregano oil-nanoemulsions: Formulation and evaluation of antibacterial and anticancer potentials, *J. Drug Delivery Sci. Technol.*, 2022, **78**, 103978.
- 41 F. Noorbakhsh, M. M. Ghasemi, M. Maghbool, M. Sorouri, S. Firoozian and M. Osanloo, Preparation, characterization, and antibacterial evaluation of nanoemulsions and chitosan nanoparticles containing lemongrass essential oil and citral against *Staphylococcus aureus* and *Pseudomonas aeruginosa*, *Bionanoscience*, 2025, **15**(1), 210.
- 42 S. Moawad, A. N. Badr, A. Farouk, N. A. Alzunaidy, F. A. Elshibani and R. Alayouni, *et al.*, Bioactivity and Nanoformulation of *Eucalyptus camaldulensis* Essential Oils: Implications for Antioxidant and Anti-inflammatory Applications, *ACS Omega*, 2025, **10**(25), 26729–26742.
- 43 C. Gago, A. Serralheiro and M. D. G. Miguel, Anti-inflammatory activity of thymol and thymol-rich essential oils: Mechanisms, applications, and recent findings, *Molecules*, 2025, **30**(11), 2450.
- 44 L. Nazakat, S. Ali, M. Summer, F. Nazakat, S. Noor and A. Riaz, Pharmacological modes of plant-derived compounds for targeting inflammation in rheumatoid arthritis: A comprehensive review on immunomodulatory perspective, *Inflammopharmacology*, 2025, 1–45.
- 45 M. Marrelli, M. De Luca, C.-C. Toma, F. Grande, M. A. Occhiuzzi and R. Caruso, *et al.*, Enhancing the nitric oxide inhibitory activity using a combination of plant essential oils and mixture design approach, *Heliyon*, 2024, **10**(10), e31080.
- 46 R. Najafi-Taher, B. Ghaemi and A. Amani, Delivery of adapalene using a novel topical gel based on tea tree oil nano-emulsion: Permeation, antibacterial and safety assessments, *Eur. J. Pharm. Sci.*, 2018, **120**, 142–151.
- 47 N. Meng, C. Zhou, Z. Sun, X. Chen, S. Xiong and M. Tao, *et al.*, Tailored gelatin methacryloyl-based hydrogel with near-infrared responsive delivery of Qiai essential oils boosting reactive oxygen species scavenging, antimicrobial, and anti-inflammatory activities for diabetic wound healing, *Int. J. Biol. Macromol.*, 2024, **263**, 130386.
- 48 M. Tao, Z. Sun, H. Wang, N. Meng, X. Chen and J. Mao, *et al.*, An NIR-responsive “4A hydrogel” encapsulating wormwood essential oil: through antibacterial, antioxidant, anti-inflammation, and angiogenic to promote diabetic wound healing, *Mater. Today Bio*, 2025, **32**, 101751.
- 49 F. Mohamed Abdoul-Latif, A. Ainane, I. Houmed Aboubaker, J. Mohamed and T. Ainane, Exploring the potent anticancer activity of essential oils and their bioactive compounds: Mechanisms and prospects for future cancer therapy, *Pharmaceuticals*, 2023, **16**(8), 1086.
- 50 H. M. Fahmy and A. M. Hamad, Development of a Lemon-peppermint Essential Oil Nanoemulsion Blend: Effects on *Bacillus* spp. Inhibition, A549 Lung Cancer Cell Viability, Cell Cycle Progression, and Genotoxicity, *Cell Biochem. Biophys.*, 2025, 1–18.
- 51 M. C. Velho, B. F. Bissacotti, A. R. Viana, L. Pappis, Â. O. Sobroza and A. Krause, *et al.*, Eugenol-loaded nanoemulsions: Antiproliferative activity against breast cancer cells and hemocompatibility, *J. Drug Delivery Sci. Technol.*, 2024, **101**, 106248.
- 52 S. Hesami, S. Safi, K. Larijani, H. N. Badi, V. Abdossi and M. Hadidi, Synthesis and characterization of chitosan nanoparticles loaded with greater celandine (*Chelidonium majus* L.) essential oil as an anticancer agent on MCF-7 cell line, *Int. J. Biol. Macromol.*, 2022, **194**, 974–981.
- 53 B. P. Mahanta, P. K. Bora, P. Kemprai, G. Borah, M. Lal and S. Haldar, Thermolabile essential oils, aromas and



- flavours: Degradation pathways, effect of thermal processing and alteration of sensory quality, *Food Res. Int.*, 2021, **145**, 110404.
- 54 Y. Tan, Q. Liang, Q. Hong, S. Zhang, T. Jiang and Z. Li, *et al.*, Preparation and characterization of Zein/sodium alginate nanoparticle-stabilised *Artemisia argyi* essential oil Pickering emulsions for agricultural antifungal applications, *Chem. Eng. J.*, 2025, **520**, 165792.
- 55 M. Perricone, E. Arace, M. R. Corbo, M. Sinigaglia and A. Bevilacqua, Bioactivity of essential oils: a review on their interaction with food components, *Front. Microbiol.*, 2015, **6**, 76.
- 56 S. A. Saldaña-Mendoza, M. L. Chávez-González, N. Ramírez-Guzmán, S. Pacios-Michelena and C. N. Aguilar, Technological trends in the extraction of essential oils, *Environ. Quality Manage.*, 2022, **32**(1), 441–450.
- 57 A. P. Chiriac, A. G. Rusu, L. E. Nita, V. M. Chiriac, I. Neamtu and A. Sandu, Polymeric carriers designed for encapsulation of essential oils with biological activity, *Pharmaceutics*, 2021, **13**(5), 631.
- 58 H. Alipanah, M. Farjam, E. Zarenezhad, G. Roozitalab and M. Osanloo, Chitosan nanoparticles containing limonene and limonene-rich essential oils: potential phytotherapy agents for the treatment of melanoma and breast cancers, *BMC Complementary Med. Ther.*, 2021, **21**(1), 186.
- 59 G. Roozitalab, Y. Yousefpoor, A. Abdollahi, M. Safari, F. Rasti and M. Osanloo, Antioxidative, anticancer, and antibacterial activities of a nanoemulsion-based gel containing *Myrtus communis* L. essential oil, *Chem. Pap.*, 2022, **76**(7), 4261–4271.
- 60 H. Rajabi, S. Sedaghati, G. Rajabzadeh and A. M. Sani, Characterization of microencapsulated spinach extract obtained by spray-drying and freeze-drying techniques and its use as a source of chlorophyll in a chewing gum based on *Pistacia atlantica*, *Food Hydrocolloids*, 2024, **150**, 109665.
- 61 H. Rajabi and S. Sedaghati, Nutraceutical dark chocolate: A delivery system for double-encapsulated extracts of *Crocus sativus* L., *Rosa damascena*, *Melissa officinalis* L., and *Echium amoenum*, *LWT*, 2024, **198**, 116036.
- 62 Z. Zheng, H. Zhang, J. Yang, X. Liu, L. Chen and W. Li, *et al.*, Recent advances in structural and functional design of electrospun nanofibers for wound healing, *J. Mater. Chem. B*, 2025, **13**(18), 5226–5263.
- 63 Y. Tomar, N. Pandit, S. Priya and G. Singhvi, Evolving trends in nanofibers for topical delivery of therapeutics in skin disorders, *ACS Omega*, 2023, **8**(21), 18340–18357.
- 64 A. Sosnik, J. das Neves and B. Sarmiento, Mucoadhesive polymers in the design of nano-drug delivery systems for administration by non-parenteral routes: A review, *Prog. Polym. Sci.*, 2014, **39**(12), 2030–2075.
- 65 I. S. Bayer, Recent advances in mucoadhesive interface materials, mucoadhesion characterization, and technologies, *Adv. Mater. Interfaces*, 2022, **9**(18), 2200211.
- 66 K.-C. Lin, H.-Y. Lin, C.-Y. Yang, Y.-L. Chu, R.-H. Xie and C.-M. Wang, *et al.*, Inhalable mucociliary-on-chip system revealing pulmonary clearance dynamics in nanodrug delivery, *ACS Nano*, 2025, **19**(2), 2228–2244.
- 67 X. Wang, J. Zhu, T. Tang, L. Yang, X. Chen and S. Meng, *et al.*, Carboxymethyl chitosan coating infused with linalool-loaded molten globular β -Lactoglobulin nanoparticles for extended preservation of fresh-cut apples, *Food Chem.*, 2024, **460**, 140578.
- 68 A. G. Alkhatami, M. Ashry, O. Al Kamaly, M. H. El-Sayed, A. Atwa and E. M. El-Fakharany, Fabrication of α -lactalbumin-coated chamomile nano-emulsion for their synergistic anticancer and anti-inflammatory applications, *Med. Oncol.*, 2025, **42**(6), 209.
- 69 S. Peng, J. Zhao, Y. Wang, F. Chen, X. Hu and L. Ma, *et al.*, Combination of α -lactalbumin and gum arabic for microencapsulation of *L*-menthol: The effects on flavor release during storage and rehydration, *Food Res. Int.*, 2023, **167**, 112632.
- 70 M. Y. A. Al-Salih, V. Poursmaeil, F. Davoodi-Dehaghani, H. N. Haghghi and M. H. Tabrizi, Study the Anticancer Properties of Thymol-Loaded PEGylated Bovine Serum Albumin Nanoparticles Conjugated with Folic Acid, *Chem. Biodiversity*, 2023, **20**(11), e202301122.
- 71 W. R. Glomm, P. P. Molesworth, E. M. Sandru, L. T. Truong, A. Brunsvik and H. Johnsen, Microencapsulation of peppermint oil by complex coacervation and subsequent spray drying using bovine serum albumin/gum acacia and an oxidized starch crosslinker, *Appl. Sci.*, 2021, **11**(9), 3956.
- 72 S.-J. Yu, S.-M. Hu, Y.-Z. Zhu, S. Zhou, S. Dong and T. Zhou, Pickering emulsions stabilized by soybean protein isolate/chitosan hydrochloride complex and their applications in essential oil delivery, *Int. J. Biol. Macromol.*, 2023, **250**, 126146.
- 73 M. Hadidi, A. Motamedzadegan, A. Z. Jelyani and S. Khashadeh, Nanoencapsulation of hyssop essential oil in chitosan-pea protein isolate nano-complex, *LWT*, 2021, **144**, 111254.
- 74 L. Yin, Y. Cao, M. Wang, B. Kong, Q. Liu and H. Wang, *et al.*, Zein-quercetin covalent nanoparticles encapsulating oregano essential oil: Improved stability, antioxidant, and antibacterial properties, *Process Biochem.*, 2025, **149**, 248–259.
- 75 Q. Xu, Y. Pu, J. Shi, X. Xu and J. Ma, Tannic acid multipoint crosslinked casein/chitosan microcapsules loaded with oregano essential oil for fruit preservation, *Int. J. Biol. Macromol.*, 2025, 148324.
- 76 M. H. Al-Musawi, A. Khoshkalampour, H. A. S. Al-Naymi, Z. F. Shafeeq, S. P. Doust and M. Ghorbani, Optimization and characterization of carrageenan/gelatin-based nanogel containing ginger essential oil enriched electrospun ethyl cellulose/casein nanofibers, *Int. J. Biol. Macromol.*, 2023, **248**, 125969.
- 77 M. Răpă, C. Gaidau, L. Mititelu-Tartau, M.-D. Berechet, A. C. Berbecaru and I. Rosca, *et al.*, Bioactive collagen hydrolysate-chitosan/essential oil electrospun nanofibers designed for medical wound dressings, *Pharmaceutics*, 2021, **13**(11), 1939.



- 78 L. Chirilă, M. S. Stan, S. Olaru, A. Popescu, M.-C. Lite and D. Toma, *et al.*, Novel Collagen-Based Emulsions Embedded with Palmarosa Essential Oil, and Chamomile and Calendula Tinctures, for Skin-Friendly Textile Materials, *Materials*, 2024, **17**(15), 3867.
- 79 K. Huang, Z. Jinzhong, T. Zhu, Y. Morsi, A. Aldalbahi and M. El-Newehy, *et al.*, PLCL/Silk fibroin based antibacterial nano wound dressing encapsulating oregano essential oil: Fabrication, characterization and biological evaluation, *Colloids Surf., B*, 2020, **196**, 111352.
- 80 L. Lin, C. Luo, C. Li, M. A. Abdel-Samie and H. Cui, Eugenol/silk fibroin nanoparticles embedded Lycium barbarum polysaccharide nanofibers for active food packaging, *Food Packag. Shelf Life*, 2022, **32**, 100841.
- 81 N. S. Farrag, A. Shetta and W. Mamdouh, Green tea essential oil encapsulated chitosan nanoparticles-based radiopharmaceutical as a new trend for solid tumor theranosis, *Int. J. Biol. Macromol.*, 2021, **186**, 811–819.
- 82 K. Saboori, M. Nassira, M. Safari, N. Namdar, Z. Montaseri and M. Osanloo, Antibacterial activity of a conventional hydrogel and a nanoparticle based hydrogel containing *Satureja khuzestanica* essential oil, *Sci. Rep.*, 2025, **15**(1), 21267.
- 83 E. Zarenezhad, M. H. Afsarian, H. Alipanah, F. Yarian, H. Moradi and H.-E. Khalaf, *et al.*, Development of Alginate and Chitosan Nanoparticles as carriers of *Zingiber officinale* essential oil for enhancement of its Anticancer, Antibacterial, and antifungal activities, *Bionanoscience*, 2024, **14**(3), 3301–3312.
- 84 N. Gan, Q. Li, Y. Li, M. Li, Y. Li and L. Chen, *et al.*, Encapsulation of lemongrass essential oil by bilayer liposomes based on pectin, gum Arabic, and carrageenan: characterization and application in chicken meat preservation, *Int. J. Biol. Macromol.*, 2024, **281**, 135706.
- 85 L. Qiu, M. Zhang, B. Adhikari and L. Chang, Microencapsulation of rose essential oil in mung bean protein isolate-apricot peel pectin complex coacervates and characterization of microcapsules, *Food Hydrocolloids*, 2022, **124**, 107366.
- 86 L. M. Fonseca, M. Radünz, H. C. dos Santos Hackbart, F. T. da Silva, T. M. Camargo and G. P. Bruni, *et al.*, Electrospun potato starch nanofibers for thyme essential oil encapsulation: Antioxidant activity and thermal resistance, *J. Sci. Food Agric.*, 2020, **100**(11), 4263–4271.
- 87 J. B. Pires, F. N. Dos Santos, E. P. da Cruz, L. M. Fonseca, T. J. Siebeneichler and G. S. Lemos, *et al.*, Starch extraction from avocado by-product and its use for encapsulation of ginger essential oil by electrospinning, *Int. J. Biol. Macromol.*, 2024, **254**, 127617.
- 88 R. S. Matche and O. O. Adeogun, Physicochemical characterisations of nanoencapsulated Eucalyptus globulus oil with gum Arabic and gum Arabic nanocapsule and their biocontrol effect on anthracnose disease of *Syzygium malaccense* Fruits, *Sci. Afr.*, 2022, **18**, e01421.
- 89 B. Ashaq, S. M. Wani, K. Rasool, S. Habib, M. A. Rouf and S. Parveen, *et al.*, Nanoencapsulation of ultrasound-assisted extracted lemongrass essential oil and bioactive from residues using gum arabic and maltodextrin as wall material, *Int. J. Biol. Macromol.*, 2025, 146800.
- 90 S. A. Razack, Y. E. Kim and H. W. Kang, κ -carrageenan-Gelatin hydrogel embedding carvacrol loaded gold nanobipyramids for treating prostate cancer via fractionated photothermal-chemotherapy, *Int. J. Biol. Macromol.*, 2025, **291**, 138974.
- 91 J. Xu, Z. Jiang, J. Peng, R. Sun, L. Zhang and Y. Chen, *et al.*, Fabrication of a protein-dextran conjugates formed oral nanoemulsion and its application to deliver the essential oil from *Alpinia zerumbet* Fructus, *Int. J. Biol. Macromol.*, 2023, **249**, 125918.
- 92 M. M. Darwish, M. S. Elneklawi and E. A. Mohamad, Aloe Vera coated Dextran Sulfate/Chitosan nanoparticles (Aloe Vera@ DS/CS) encapsulating Eucalyptus essential oil with antibacterial potent property, *J. Biomater. Sci., Polym. Ed.*, 2023, **34**(6), 810–827.
- 93 W. Liang, X. Ge, Q. Lin, W. Zhao, L. Niu and M. Muratkhan, *et al.*, pH-responsive liposomes for controlled release of *Alpinia galanga* essential oil: Investigating characteristics, stability, control release behavior, and functionality, *Ind. Crops Prod.*, 2024, **209**, 117978.
- 94 H. M. E.-S. Azzazy, A. Abdelnaser, H. Al Mulla, A. M. Sawy, S. N. Shamma and M. Elhousseiny, *et al.*, Essential Oils Extracted from *Boswellia sacra* Oleo Gum Resin Loaded into PLGA-PCL Nanoparticles: Enhanced Cytotoxic and Apoptotic Effects against Breast Cancer Cells, *ACS Omega*, 2022, **8**(1), 1017–1025.
- 95 F. S. E. El-Tokhy, D. O. Helal, S. S. A. Mageed, A. M. Mahmoud, R. I. El-Gogary and E. A. El-Ghany, *et al.*, Repurposing of linagliptin for enhanced wound healing and skin rejuvenation via chitosan-modified PLGA nanoplateforms, *Int. J. Pharm.*, 2025, 125664.
- 96 D. Ismaili, F. N. Parin, Y. Sıcak, M. Öztürk and P. Terzioğlu, Electrospun lavender essential oil-loaded polylactic acid nanofibrous mats for antioxidant applications, *Polym. Bull.*, 2024, **81**(15), 13975–13992.
- 97 D. Wang, Z. Sun, J. Sun, F. Liu, L. Du and D. Wang, Preparation and characterization of polylactic acid nanofiber films loading Perilla essential oil for antibacterial packaging of chilled chicken, *Int. J. Biol. Macromol.*, 2021, **192**, 379–388.
- 98 M. Li, Y. Yang, J. Li, R. Qi, Y. Pang and J. Wang, *et al.*, Enhancement of scald wound healing using *Blumea balsamifera* oil-loaded nanofiber membranes, *Mater. Today Commun.*, 2025, 112670.
- 99 I. Partheniadis, E. Zarafidou, K. E. Litinas and I. Nikolakakis, Enteric release essential oil prepared by co-spray drying methacrylate/polysaccharides—Influence of starch type, *Pharmaceutics*, 2020, **12**(6), 571.
- 100 T. Jiang, D. Wang, X. Zhang, Q. Yang, Q. Huang and X. Ju, *et al.*, Electrospinning of chitosan/polyvinyl alcohol Pickering emulsion with tea tree essential oil loaded for anti-infection wound dressings, *Mater. Chem. Phys.*, 2024, **311**, 128561.



- 101 P. K. Chaudhary, D. Saini, P. Mishra, K. Pandav and R. Prasad, Essential oil active constituents loaded PVA nanofibers enhance antibiofilm activity against *Candida albicans* and *Candida tropicalis*, *J. Drug Delivery Sci. Technol.*, 2024, **98**, 105871.
- 102 G. Rahimi, S. Yousefnia, L. Angnes and M. Negahdary, Design a PEGylated nanocarrier containing lemongrass essential oil (LEO), a drug delivery system: Application as a cytotoxic agent against breast cancer cells, *J. Drug Delivery Sci. Technol.*, 2023, **80**, 104183.
- 103 X. Wang, L. Huang, Q. Du, J. Li, Q. Zheng and Y. Chen, *et al.*, Pickering emulsions embedded in *Bletilla striata* polysaccharide based nanogel for enhancing skin-whitening effect of essential oils, *Int. J. Pharm.*, 2024, **667**, 124918.
- 104 R. Ranjbar, E. Zarenezhad, A. Abdollahi, M. Nasrizadeh, S. Firooziyani and N. Namdar, *et al.*, Nanoemulsion and nanogel containing *Cuminum cyminum* L essential oil: antioxidant, anticancer, antibacterial, and antilarval properties, *J. Trop. Med.*, 2023, **2023**(1), 5075581.
- 105 E. M. Marques, L. G. Santos Andrade, L. M. Rebelo Alencar, E. R. Dias Rates, R. M. Ribeiro and R. C. Carvalho, *et al.*, Nanotechnological formulation incorporating *Pectis brevipedunculata* (Asteraceae) essential oil: An ecofriendly approach for leishmanicidal and anti-inflammatory therapy, *Polymers*, 2025, **17**(3), 379.
- 106 S. D. Kayiran, U. M. G. Bolgen, T. Cevikelli, S. Kızılyıldırım, B. Yildir and E. Ferahoglu, *et al.*, Chemical composition and antibacterial properties of microemulsion and microemulgel formulations containing *Lavandula angustifolia* Mill. essential oils, *Ind. Crops Prod.*, 2025, **226**, 120654.
- 107 F. N. Parin, A. Gün, R. İlhan and U. Parin, Effects of essential oil on the properties of egg white/polyacrylamide (EW/PAAm) Pickering emulsion hydrogels (PEHs) via UV crosslinking, *Polym. Bull.*, 2025, 1–24.
- 108 S. S. Nedel, S. da Silva Gündel, M. L. Machado, F. B. O. Baptista, B. Klein and F. Candido, *et al.*, Nanostructured delivery of lavender essential oils improves safety and neuroprotective efficacy *in vivo*, *J. Drug Delivery Sci. Technol.*, 2025, 107652.
- 109 V. Bhavana, P. S. Chary, N. Rajana, G. Devabattula, S. Sau and C. Godugu, *et al.*, Multimodal lemongrass oil based topical nanoemulgel ingrained with ferulic acid for wound healing activity, *J. Mol. Liq.*, 2023, **389**, 122870.
- 110 F. Mirzajani, R. Ebrahimi, W. Weisany and O. Khademi, Biopolymer-based active packaging with TiO₂ and nano-encapsulated essential oils improves postharvest stability of fresh-cut kale, *Food Chem.:X*, 2025, 103141.
- 111 S. A. Alsakhawy, H. H. Baghdadi, M. A. El-Shenawy and L. S. El-Hosseiny, Enhancement of lemongrass essential oil physicochemical properties and antibacterial activity by encapsulation in zein-caseinate nanocomposite, *Sci. Rep.*, 2024, **14**(1), 17278.
- 112 R. N. F. Nazurah, M. Noranizan, M. Nor-Khaizura and Z. N. Hanani, Chitosan nanoparticles incorporate with curry leaf essential oil: Physicochemical characterization and *in vitro* release properties, *Int. J. Biol. Macromol.*, 2024, **273**, 132972.
- 113 B. A. Samling, Z. Assim, W.-Y. Tong, C.-R. Leong, S. Ab Rashid and N. N. S. N. M. Kamal, *et al.*, *Cynometra cauliflora* essential oils loaded-chitosan nanoparticles: Evaluations of their antioxidant, antimicrobial and cytotoxic activities, *Int. J. Biol. Macromol.*, 2022, **210**, 742–751.
- 114 T. Jawaid, R. Anwer, S. Ahmed, O. A. Alkhamees, A. I. Foudah and T. M. Aljarba, *et al.*, Chitosan-modified nanoliposomes loaded with tea tree oil: A novel topical gel for managing infections, *J. Drug Delivery Sci. Technol.*, 2025, 107403.
- 115 G. E. Maraulo, C. dos Santos Ferreira, C. E. Beaufort, M. G. Ugarte and M. F. Mazzobre, Encapsulation of bergamot essential oil components in β -cyclodextrin by ultrasound-assisted co-precipitation method: Optimization, characterization, and antibacterial activity, *Food Bioprocess Technol.*, 2024, **17**(12), 5386–5400.
- 116 Y. Y. Marinho, E. A. P. Silva, J. Y. Oliveira, D. M. Santos, B. S. Lima and D. S. Souza, *et al.*, Preparation, physicochemical characterization, docking and antiarrhythmic effect of d-limonene and d-limonene hydroxypropyl- β -cyclodextrin complex, *J. Drug Delivery Sci. Technol.*, 2022, **71**, 103350.
- 117 P. Taherian, M. S. Nourbakhsh, A. A. Mehrizi and M. Hashemi, Encapsulation of Frankincense Essential Oil by Microfluidic and Bulk Approaches: A Comparative Study, *Fibers Polym.*, 2022, **23**(10), 2970–2980.
- 118 Y. Du, L. Mo, X. Wang, H. Wang, X.-H. Ge and T. Qiu, Preparation of mint oil microcapsules by microfluidics with high efficiency and controllability in release properties, *Microfluid. Nanofluid.*, 2020, **24**(6), 42.
- 119 S. A. Alsakhawy, H. H. Baghdadi, M. A. El-Shenawy, S. A. Sabra and L. S. El-Hosseiny, Encapsulation of thymus vulgaris essential oil in caseinate/gelatin nanocomposite hydrogel: *In vitro* antibacterial activity and *in vivo* wound healing potential, *Int. J. Pharm.*, 2022, **628**, 122280.
- 120 M. M. Agwa, S. Sabra, N. A. Atwa, H. A. Dahdooh, R. M. Lithy and H. Elmotasem, Potential of frankincense essential oil-loaded whey protein nanoparticles embedded in frankincense resin as a wound healing film based on green technology, *J. Drug Delivery Sci. Technol.*, 2022, **71**, 103291.
- 121 H. Farahani, A. Barati, M. Arjomandzadegan and E. Vatankhah, Nanofibrous cellulose acetate/gelatin wound dressing endowed with antibacterial and healing efficacy using nanoemulsion of *Zataria multiflora*, *Int. J. Biol. Macromol.*, 2020, **162**, 762–773.
- 122 A. Sharifpour, M. J. Dakheli, S. Rahimi and A. Bassiri, Optimization of bitter orange (*Citrus aurantium* L.) essential oil microencapsulation through spout fluidized bed drying, *J. Food Meas. Charact.*, 2025, **19**(1), 89–107.
- 123 A. Touati, A. Mairi, N. A. Ibrahim and T. Idres, Essential oils for biofilm control: mechanisms, synergies, and translational challenges in the era of antimicrobial resistance, *Antibiotics*, 2025, **14**(5), 503.



- 124 M. A. A. Agreles, I. D. L. Cavalcanti and I. M. F. Cavalcanti, The role of essential oils in the inhibition of efflux pumps and reversion of bacterial resistance to antimicrobials, *Curr. Microbiol.*, 2021, **78**(10), 3609–3619.
- 125 H. Cui, C. Zhang, C. Li and L. Lin, Antibacterial mechanism of oregano essential oil, *Ind. Crops Prod.*, 2019, **139**, 111498.
- 126 N. Gautam, A. K. Mantha and S. Mittal, Essential oils and their constituents as anticancer agents: a mechanistic view, *BioMed Res. Int.*, 2014, **2014**(1), 154106.
- 127 I. R. Singh, A. K. Pulikkal, A. PN, T. Laldingliani and A. Kumar, Nanoemulsion of Lemon Grass (*Cymbopogon flexuosus*) Essential Oil: Stability, Molecular Dynamics, Anticancer, and Antibacterial Potential, *Ind. Eng. Chem. Res.*, 2025, **64**(51), 24300–24316.
- 128 M.-M. Zhang, T. Wen, M.-W. Cui and Z.-L. Guo, Anti-Inflammatory Properties of Agarwood (*Aquilaria* Spp.): An Integrated Review of Phytochemistry, Molecular Mechanisms, and Therapeutic Applications, *Drug Des., Dev. Ther.*, 2026, 1–15.
- 129 Y. Huang, H. Ebrahimi, E. Berselli, M. C. Foti and R. Amorati, Essential Oils as Antioxidants: Mechanistic Insights from Radical Scavenging to Redox Signaling, *Antioxidants*, 2025, **15**(1), 37.
- 130 F. Jiang, X. Huang, X. Chen and Y. Xian, Health benefits of plant-derived essential oils in mitigating oxidative stress: a comprehensive review, *Cogent Food Agric.*, 2025, **11**(1), 2564258.
- 131 E. R. Brannon, M. V. Guevara, N. J. Pacifici, J. K. Lee, J. S. Lewis and O. Eniola-Adefeso, Polymeric particle-based therapies for acute inflammatory diseases, *Nat. Rev. Mater.*, 2022, **7**(10), 796–813.
- 132 T. Das, M. Das, S. Sultana and R. Swain, Stimuli-responsive nanogels in wound care: A comprehensive review, *Next Nanotechnol.*, 2025, **8**, 100260.
- 133 E. J. Delgado-Pujol, G. Martínez, D. Casado-Jurado, J. Vázquez, J. León-Barberena and D. Rodríguez-Lucena, *et al.*, Hydrogels and nanogels: pioneering the future of advanced drug delivery systems, *Pharmaceutics*, 2025, **17**(2), 215.
- 134 V. Khwaza and O. O. Oyedeji, Polymer-Based Scaffolds Incorporating Selected Essential Oil Components for Wound Healing: A Review, *Pharmaceutics*, 2025, **17**(10), 1313.
- 135 W. Zhu, Y. Dong, T. Wu, H. Jing, Z. Li and X. Yu, *et al.*, Beta-cyclodextrin inclusion complexes of citral and linalool inhibit *Escherichia coli* on cooked chicken: Focus on their synergistic antibacterial effects, *Food Chem.:X*, 2025, 103248.
- 136 H. Rajabi and S. M. A. Razavi, Co-encapsulation of saffron petal and *Stachys schtscheglevii* extracts via complex coacervation and graphene oxide-assisted spray drying for co-delivery and stability enhancement, *LWT*, 2025, **223**, 117705.
- 137 S. Bahraminejad, M. Mousavi, G. Askari, M. Gharaghani and H. Pourramzan, Octenylsuccinated alginate as a delivery agent for encapsulation of bergamot essential oil: Preparation, functional properties and release behavior, *Int. J. Biol. Macromol.*, 2024, **282**, 136616.
- 138 B. M. Worku, N. T. Shibeshi, T. Zhiyuan, J.-Y. Cho and J.-B. Eun, Encapsulated essential oils in protein-polysaccharide biopolymers: Characteristics and applications in the biomedical and food industries, *Food Sci. Biotechnol.*, 2025, **34**(4), 851–869.
- 139 G. S. Vishwakarma, N. Gautam, J. N. Babu, S. Mittal and V. Jaitak, Polymeric encapsulates of essential oils and their constituents: A review of preparation techniques, characterization, and sustainable release mechanisms, *Polym. Rev.*, 2016, **56**(4), 668–701.
- 140 S. Rojas-Moreno, G. Osorio-Revilla, T. Gallardo-Velázquez, F. Cárdenas-Bailón and G. Meza-Márquez, Effect of the cross-linking agent and drying method on encapsulation efficiency of orange essential oil by complex coacervation using whey protein isolate with different polysaccharides, *J. Microencapsulation*, 2018, **35**(2), 165–180.
- 141 B. Muhoza, S. Xia, X. Wang, X. Zhang, Y. Li and S. Zhang, Microencapsulation of essential oils by complex coacervation method: Preparation, thermal stability, release properties and applications, *Crit. Rev. Food Sci. Nutr.*, 2022, **62**(5), 1363–1382.
- 142 E. Ansarifard and F. Moradinezhad, Encapsulation of thyme essential oil using electrospun zein fiber for strawberry preservation, *Chem. Biol. Technol. Agric.*, 2022, **9**(1), 2.
- 143 X. Liu, F. Xue and B. Adhikari, Encapsulation of essential oils using hemp protein isolate–gum Arabic complex coacervates and evaluation of the capsules, *Sustainable Food Technol.*, 2023, **1**(3), 426–436.
- 144 S. C. Andrade, A. F. Uchôa, A. L. Formiga, A. L. Cardoso, N. S. Magalhães and O. França R, *et al.*, Development of Optimized *Origanum vulgare* L. Essential Oil-Loaded Chitosan/Gum Arabic Nanocapsules by Complex Coacervation, *ACS Omega*, 2025, **10**(42), 50652–50665.
- 145 E. J. D. de Souza, D. H. Kringel, A. R. G. Dias and E. da Rosa Zavareze, Polysaccharides as wall material for the encapsulation of essential oils by electrospun technique, *Carbohydr. Polym.*, 2021, **265**, 118068.
- 146 P. Kumari, B. Ghosh and S. Biswas, Nanocarriers for cancer-targeted drug delivery, *J. Drug Targeting*, 2016, **24**(3), 179–191.
- 147 J. Yamine, N.-E. Chihib, A. Gharsallaoui, A. Ismail and L. Karam, Advances in essential oils encapsulation: development, characterization and release mechanisms, *Polym. Bull.*, 2024, **81**(5), 3837–3882.
- 148 S. F. Tabatabaeain, E. Karimi and M. Hashemi, Satureja khuzistanica essential oil-loaded solid lipid nanoparticles modified with chitosan-folate: Evaluation of encapsulation efficiency, cytotoxic and pro-apoptotic properties, *Front. Chem.*, 2022, **10**, 904973.
- 149 A. Jobdeedamrong, R. Jenjob and D. Crespy, Encapsulation and release of essential oils in functional silica nanocontainers, *Langmuir*, 2018, **34**(44), 13235–13243.



- 150 C.-C. Lin and A. T. Metters, Hydrogels in controlled release formulations: network design and mathematical modeling, *Adv. Drug Delivery Rev.*, 2006, **58**(12–13), 1379–1408.
- 151 N. A. Peppas, P. Bures, W. Leobandung and H. Ichikawa, Hydrogels in pharmaceutical formulations, *Eur. J. Pharm. Biopharm.*, 2000, **50**(1), 27–46.
- 152 J.-P. Wang, X.-X. Zhang and X.-C. Wang, Preparation, characterization and permeation kinetics description of calcium alginate macro-capsules containing shape-stabilize phase change materials, *Renewable Energy*, 2011, **36**(11), 2984–2991.
- 153 K. T. Laina, C. Drosou and M. Krokida, Comparative assessment of encapsulated essential oils through the innovative electrohydrodynamic processing and the conventional spray drying, and freeze-drying techniques, *Innovative Food Sci. Emerging Technol.*, 2024, **95**, 103720.
- 154 K. Varma, R. Kumar, J. George, A. Rajan, V. Vasudevan and J. H. Lakshmana, *et al.*, Characterization and controlled release kinetics of Co-encapsulated spice essential oils: Its impact on preserving flavors in thermally processed ready-to-eat (RTE) chicken cubes, *Food Biosci.*, 2025, 107520.
- 155 S. Das, V. K. Singh, A. K. Chaudhari, A. K. Dwivedy and N. K. Dubey, Co-encapsulation of Pimpinella anisum and Coriandrum sativum essential oils based synergistic formulation through binary mixture: Physico-chemical characterization, appraisal of antifungal mechanism of action, and application as natural food preservative, *Pestic. Biochem. Physiol.*, 2022, **184**, 105066.
- 156 J. Feng, C. Liuyang, W. Yan, Z. Weiguang, W. Hao and Y. Shaobowen, *et al.*, Preparation of temperature-responsive pickering emulsions for encapsulating compound essential oils and their application in fresh noodle preservation, *Food Chem.*, 2025, **479**, 143822.
- 157 H. Emtiazi, A. Salari Sharif, M. Hemati, B. Fatemeh Haghirsadat and A. Pardakhti, Comparative study of nano-liposome and nano-niosome for delivery of achillea millefolium essential oils: development, optimization, characterization and their cytotoxicity effects on cancer cell lines and antibacterial activity, *Chem. Biodiversity*, 2022, **19**(10), e202200397.
- 158 Z. Dajic Stevanovic, E. Sieniawska, K. Glowniak, N. Obradovic and I. Pajic-Lijakovic, Natural macromolecules as carriers for essential oils: From extraction to biomedical application, *Front. Bioeng. Biotechnol.*, 2020, **8**, 563.
- 159 M. J. Nirmala, L. Durai, G. S. Anusha and R. Nagarajan, Nanoemulsion of Mentha arvensis essential oil as an anticancer agent in anaplastic thyroid Cancer cells and as an antibacterial agent in Staphylococcus aureus, *Bionanoscience*, 2021, **11**(4), 1017–1029.
- 160 E. Zarenezhad, M. Agholi, A. Ghanbariasad, A. Ranjbar and M. Osanloo, A nanoemulsion-based nanogel of Citrus limon essential oil with leishmanicidal activity against Leishmania tropica and Leishmania major, *J. Parasit. Dis.*, 2021, **45**(2), 441–448.
- 161 A. Ghanbariasad, S. Azadi, M. Agholi and M. Osanloo, The nanoemulsion-based nanogel of Artemisia dracunculus essential oil with proper activity against Leishmania tropica and Leishmania major, *Nanomed. Res. J.*, 2021, **6**(1), 89–95.
- 162 J. Movaffagh, B. R. H. Farash, V. M. Goyonlo, E. Moghaddas, M. Zarean and S. A. Shamsian, *et al.*, Pilot evaluation of thymol-loaded chitosan gel as a complementary topical therapy for cutaneous leishmaniasis, *Carbohydr. Polym. Technol. Appl.*, 2025, **9**, 100641.
- 163 F. Zhang, G. Ramachandran, R. A. Mothana, O. M. Noman, W. A. Alobaid and G. Rajivgandhi, *et al.*, Anti-bacterial activity of chitosan loaded plant essential oil against multi drug resistant K. pneumoniae, *Saudi J. Biol. Sci.*, 2020, **27**(12), 3449–3455.
- 164 M. T. Yilmaz, A. Yilmaz, P. K. Akman, F. Bozkurt, E. Dertli and A. Basahel, *et al.*, Electrospinning method for fabrication of essential oil loaded-chitosan nanoparticle delivery systems characterized by molecular, thermal, morphological and antifungal properties, *Innovative Food Sci. Emerging Technol.*, 2019, **52**, 166–178.
- 165 B. A. Alexandre, A. R. de Souza Rossin, J. Caetano, R. M. Marques, C. V. Buzanello and Z. C. Gazim, *et al.*, Production of a dressing with Ecovio[®] nanofibers produced by electrospinning containing garlic wood essential oil, *J. Mol. Liq.*, 2025, 128126.
- 166 M. R. Zare, M. Khorram, S. Barzegar, F. Asadian, Z. Zareshahrabadi and M. J. Saharkhiz, *et al.*, Antimicrobial core-shell electrospun nanofibers containing Ajwain essential oil for accelerating infected wound healing, *Int. J. Pharm.*, 2021, **603**, 120698.
- 167 P. Nezhad-Mokhtari, F. Kazeminava, B. Abdollahi, P. Gholizadeh, A. Heydari and F. Elmi, *et al.*, Matricaria chamomilla essential oil-loaded hybrid electrospun nanofibers based on polycaprolactone/sulfonated chitosan/ZIF-8 nanoparticles for wound healing acceleration, *Int. J. Biol. Macromol.*, 2023, **247**, 125718.
- 168 J. P. Paques, E. van der Linden, C. J. van Rijn and L. M. Sagis, Preparation methods of alginate nanoparticles, *Adv. Colloid Interface Sci.*, 2014, **209**, 163–171.
- 169 M. Osanloo, R. Ranjbar and E. Zarenezhad, Alginate nanoparticles containing *Cuminum cyminum* and *Zataria multiflora* essential oils with promising Anticancer and Antibacterial effects, *Int. J. Biomater.*, 2024, **2024**(1), 5556838.
- 170 S. Forgi, M. Osanloo, F. Norouzi, M. H. Amushahi, E. Zarenezhad and M. Sayadi, *et al.*, Comparative antimicrobial activity of *Zataria multiflora* essential oil nanoformulations against foodborne pathogens, *Sci. Rep.*, 2025, **15**(1), 38296.
- 171 M. Osanloo, S. Fereydonpour, A. Abdollahi and M. Safari, Development of Nanofiber Mats Impregnated With *Ferula assa-foetida* Essential Oil Nanogel for Antibacterial Wound Care, *Int. J. Biomater.*, 2025, **2025**(1), 1436095.
- 172 F. Rasti, Y. Yousefpoor, A. Abdollahi, M. Safari, G. Roozitalab and M. Osanloo, Antioxidative, anticancer, and antibacterial activities of a nanogel containing *Mentha spicata* L. essential oil and electrospun nanofibers of polycaprolactone-hydroxypropyl methylcellulose, *BMC Complementary Med. Ther.*, 2022, **22**(1), 261.



- 173 A. Celebioglu, E. Hsiung, M. Aboelkheir, R. Chowdhury, C. Altier and T. Uyar, Encapsulation of Essential Oil-Cyclodextrin Inclusion Complexes in Electrospun Pullulan Nanofibers: Enhanced Storage Stability and Antibacterial Property for Geraniol and Linalool, *Food Bioprocess Technol.*, 2025, **18**(2), 1296–1310.
- 174 M. Rafya, A. Hafidi, N. Zehhar and F. Benkhalti, Optimization of three-component essential oil-loaded nanoemulsions in combination using D-optimal mixture design, *S. Afr. J. Bot.*, 2023, **159**, 472–481.
- 175 L. Torres Neto, M. L. G. Monteiro, B. D. da Silva, M. A. M. Machado, Y. D. S. Mutz and C. A. Conte-Junior, Ultrasound-assisted nanoemulsion loaded with optimized antibacterial essential oil blend: A new approach against *Escherichia coli*, *Staphylococcus aureus*, and *Salmonella Enteritidis* in trout (*Oncorhynchus mykiss*) fillets, *Foods*, 2024, **13**(10), 1569.
- 176 Y. Jamir, S. R. Kumari, S. Das, M. Bhushan, M. A. P and S. Ghatak, *et al.*, Enhanced synergistic antioxidant and antibacterial effects of stable nanoemulsions prepared from blends of thyme, black pepper, cinnamon, and garlic essential oils, *Bionanoscience*, 2025, **15**(1), 70.
- 177 A. Ghanbariasad, M. Osanloo, S. Hatami, S. Khaksar, E. Zarenezhad and R. Ranjbar, *et al.*, Synthesis, characterization, and development of alpha-pinene nanoemulsion as an apoptotic inducer with cytotoxicity activity on human melanoma and breast cancer, *Chem. Pap.*, 2024, **78**(2), 1181–1191.
- 178 I. Nayila, S. Sharif, M. S. Lodhi, R. Ullah, A. Alotaibi and T. Maqbool, *et al.*, Formulation, characterization and evaluation of anti-breast cancer activity of 2-carene nanoemulsion; *in silico*, *in vitro* and *in vivo* study, *Arabian J. Chem.*, 2024, **17**(9), 105937.
- 179 W. A. Al-Otaibi and S. M. AlMotwaa, Oxaliplatin-loaded nanoemulsion containing *Teucrium polium* L. essential oil induces apoptosis in Colon cancer cell lines through ROS-mediated pathway, *Drug Delivery*, 2022, **29**(1), 2190–2205.
- 180 A. Karimivaselabadi, M. Osanloo, A. Ghanbariasad, E. Zarenezhad and H. Hosseini, Comparison of chitosan nanoparticles containing *Lippia citriodora* essential oil and citral on the induction of apoptosis in A375 melanoma cells, *BMC Complementary Med. Ther.*, 2023, **23**(1), 435.
- 181 M. Osanloo, H. Alipanah, M. Farjam, A. Taheri and E. Zarenezhad, Anticancer activity of Chitosan nanoparticles containing *Satureja khuzistanica* essential oil, and carvacrol against human Melanoma and Breast Cancer, *Russ. J. Bioorg. Chem.*, 2023, **49**(3), 594–601.
- 182 H. Alipanah, F. Rasti, E. Zarenezhad, A. Dehghan, B. Sahebazar and M. Osanloo, Comparison of anticancer effects of carvone, carvone-rich essential oils, and chitosan nanoparticles containing each of them, *Biointerface Res. Appl. Chem.*, 2022, **12**, 5716–5726.
- 183 K. E. Woodworth, N. I. Callaghan and L. Davenport Huyer, Biomaterial strategies for targeted intracellular delivery to phagocytes, *Adv. Funct. Mater.*, 2026, **36**(1), e08761.
- 184 F. Yarian, Y. Yousefpoor, S. Hatami, E. Zarenezhad, E. Peisepar and H. Alipanah, *et al.*, Comparison effects of alginate nanoparticles containing *syzygium aromaticum* essential oil and eugenol on apoptotic regulator genes and viability of A-375 and MCF-7 cancer cell lines, *Bionanoscience*, 2023, **13**(3), 911–919.
- 185 S. Hatami, Y. Mansoori, R. Heiran, A. Taheri, A. Ghasemian and M. Osanloo, Alginate nanoparticles containing *Rosmarinus officinalis* essential oil and α -pinene: cytotoxicity and effect on apoptotic-involved genes in human melanoma and breast cancer cell lines, *Nanomed. Res. J.*, 2023, **8**(3), 301–310.
- 186 M. Osanloo, S. Pishamad, A. Ghanbariasad, E. Zarenezhad, M. Alipanah and H. Alipanah, Comparison effects of *Ferula gummosa* essential oil and Beta-pinene Alginate nanoparticles on human melanoma and breast cancer cells proliferation and apoptotic index in short term normobaric hyperoxic model, *BMC Complementary Med. Ther.*, 2023, **23**(1), 428.
- 187 F. Karami, M. Osanloo, H. Alipanah, E. Zarenezhad, F. Moghimi and A. Ghanbariasad, Comparison of the efficacy of alginate nanoparticles containing *Cymbopogon citratus* essential oil and citral on melanoma and breast cancer cell lines under normoxic and hypoxic conditions, *BMC Complementary Med. Ther.*, 2024, **24**(1), 372.
- 188 S. Azadi, M. Osanloo, E. Zarenezhad, M. Farjam, A. Jalali and A. Ghanbariasad, Nano-scaled emulsion and nanogel containing *Mentha pulegium* essential oil: cytotoxicity on human melanoma cells and effects on apoptosis regulator genes, *BMC Complementary Med. Ther.*, 2023, **23**(1), 6.
- 189 V. Mossmann, P. Weimer, K. A. A. Nunes, R. C. Rossi and L. S. Koester, Essential Oil Extracted from the Leaves of *Curcuma Longa* L.: Application of an Agro-Industrial Residue in the Development of Anti-Inflammatory Nanoemulsions Intended for Skin Delivery, *Chem. Afr.*, 2024, **7**(4), 1849–1864.
- 190 R. L. De Souza, C. de Oliveira Melo, L. C. F. Opretzka, E. L. Wändega, C. F. Villarreal and E. E. Oliveira, Nanoemulsion Improves the Anti-inflammatory Activity of Carvacrol upon Oral Administration, *Rev. Bras. Farmacogn.*, 2023, **33**(1), 164–172.
- 191 R. D. Naseer, F. Muhammad, B. Aslam and M. N. Faisal, Anti-arthritis effects of geranium essential oil loaded chitosan nanoparticles in Freund's complete adjuvant induced arthritic rats through down-regulation of inflammatory cytokines, *Inflammopharmacology*, 2023, **31**(4), 1893–1912.
- 192 K. M. Alshehri and E. M. Abdella, Development of ternary nanoformulation comprising bee pollen-thymol oil extracts and chitosan nanoparticles for anti-inflammatory and anticancer applications, *Int. J. Biol. Macromol.*, 2023, **242**, 124584.
- 193 Z. Kanwal, B. Akhtar, B. Aslam and M. I. Arshad, Carvone-loaded chitosan nanoparticles alleviate joint destruction by downregulating the expression of pro, inflammatory cytokines and MMP-13 in adjuvant-induced rat model, *Inflammopharmacology*, 2025, **33**(1), 269–289.



- 194 Y. Hao, X. Lin, W. Liu, T. Jiang, X. Zhang and S. Yang, *et al.*, Development of nanofiber facial mask inspired by the multi-function of dried ginger (*Zingiberis Rhizoma*) essential oil, *Sci. Rep.*, 2025, **15**(1), 402.
- 195 X. Wu, Z. Liu, J. Liu, S. He and W. Shao, Development of novel intelligent and edible dual-functional electrospun nanofiber films for shrimp preservation and freshness monitoring in real-time, *Food Biosci.*, 2024, **61**, 104828.
- 196 A. Valizadeh, M. Hosseinzadeh, R. Heiran, S. Hatami, A. Hosseini-pour and M. Osanloo, Alginate nanoparticles containing *Lavandula angustifolia* essential oil as a potential potent, biocompatible and low-cost antitumor agent, *Polym. Bull.*, 2024, **81**(2), 1861–1874.
- 197 A. Tomaszewska, B. Kost, M. Brzeziński, M. Nowicka, M. Krupa and T. Rechciński, *et al.*, Targeted and safe delivery of colchicine via polymeric nanocarriers for potential atherosclerosis therapy with in vitro and in vivo evaluation, *Sci. Rep.*, 2025, **15**(1), 31334.
- 198 J. Yammine, A. Fathima, A. Gharsallaoui, M. Z. Masalmeh, M. Hasan and H. C. Yalcin, *et al.*, Nanoencapsulation mitigates the toxicity of thymol in human cells and zebrafish embryos, *Int. J. Food Prop.*, 2025, **28**(1), 2573183.
- 199 M. E. Rad, C. Soyulukan, P. K. Kulabhusan, B. N. Günaydin and M. Yuçe, Material and design toolkit for drug delivery: state of the art, trends, and challenges, *ACS Appl. Mater. Interfaces*, 2023, **15**(48), 55201–55231.
- 200 F. Eker, H. Duman, E. Akdaşçi, E. Bolat, S. Sarıtaş and S. Karav, *et al.*, A comprehensive review of nanoparticles: from classification to application and toxicity, *Molecules*, 2024, **29**(15), 3482.
- 201 K. A. Wojtunik-Kulesza, Toxicity of selected monoterpenes and essential oils rich in these compounds, *Molecules*, 2022, **27**(5), 1716.
- 202 C. Turek and F. C. Stintzing, Stability of essential oils: a review, *Compr. Rev. Food Sci. Food Saf.*, 2013, **12**(1), 40–53.
- 203 R. Tisserand and R. Young, *Essential oil safety: a guide for health care professionals*, Elsevier Health Sciences, 2013.
- 204 G. Benchamas, G. Huang, S. Huang and H. Huang, Preparation and biological activities of chitosan oligosaccharides, *Trends Food Sci. Technol.*, 2021, **107**, 38–44.
- 205 S. Naahidi, M. Jafari, F. Edalat, K. Raymond, A. Khademhosseini and P. Chen, Biocompatibility of engineered nanoparticles for drug delivery, *J. Controlled Release*, 2013, **166**(2), 182–194.
- 206 N. Parvin, M. Aslam, S. W. Joo and T. K. Mandal, Nanophytomedicine: harnessing plant-derived phytochemicals in nanocarriers for targeted human health applications, *Molecules*, 2025, **30**(15), 3177.
- 207 Y. Shen, H. Gwak and B. Han, Advanced manufacturing of nanoparticle formulations of drugs and biologics using microfluidics, *Analyt.*, 2024, **149**(3), 614–637.
- 208 M. MacEwan, L. Jeng, T. Kovács and E. Sallade, Clinical application of bioresorbable, synthetic, electrospun matrix in wound healing, *Bioengineering*, 2022, **10**(1), 9.
- 209 H. M. Younes, H. Kadavil, H. M. Ismail, S. A. Adib, S. Zamani and R. G. Alany, *et al.*, Overview of tissue engineering and drug delivery applications of reactive electrospinning and crosslinking techniques of polymeric nanofibers with highlights on their biocompatibility testing and regulatory aspects, *Pharmaceutics*, 2023, **16**(1), 32.
- 210 F. D. Rodríguez-Gómez, D. Monferrer, O. Penon and P. Riveragil, Regulatory pathways and guidelines for nanotechnology-enabled health products: a comparative review of EU and US frameworks, *Front. Med.*, 2025, **12**, 1544393.
- 211 A. Antonelli and F. Palma, Nanocarrier-based delivery systems for natural compounds across research stages, *Materials*, 2025, **18**(21), 4960.
- 212 Y. Wu, Y. Luo, B. Zhou, L. Mei, Q. Wang and B. Zhang, Porous metal-organic framework (MOF) Carrier for incorporation of volatile antimicrobial essential oil, *Food Control*, 2019, **98**, 174–178.
- 213 J. Huang, H. Chen, Y. Liao, X. Zhang, Z. Zhang and X. Su, *et al.*, Metal-organic framework materials for encapsulation, release and delivery of essential oils: Engineering strategies and challenges, *Chin. Chem. Lett.*, 2025, 112049.
- 214 W. Weisany, S. Yousefi, S. P. Soufiani, D. Pashang, D. J. McClements and M. Ghasemlou, Mesoporous silica nanoparticles: A versatile platform for encapsulation and delivery of essential oils for food applications, *Adv. Colloid Interface Sci.*, 2024, **325**, 103116.
- 215 D. Nithyanantham, A. Nair and U. Y. Nayak, Leveraging artificial intelligence for advancements in liquid dosage formulations in the pharmaceutical industry, *Ther. Innov. Regul. Sci.*, 2025, **59**(5), 1004–1031.
- 216 A. Zöngür and M. A. Buzpinar, AI-assisted antifungal discovery of *Aspergillus parasiticus* and *Aspergillus flavus*: investigating the potential of *Asphodelus aestivus*, *Beta vulgaris*, and *Morus alba* plant leaf extracts, *Model. Earth Syst. Environ.*, 2023, **9**(2), 2745–2756.
- 217 D. U. Kapoor, J. B. Sharma, S. M. Gandhi, B. G. Prajapati, K. Thanawuth and S. Limmatvapirat, *et al.*, AI-driven design and optimization of nanoparticle-based drug delivery systems, *Sci. Eng. Health Stud.*, 2024, 24010003.
- 218 H. A. Gad, E. A. Mukhammadiev, G. Zengen, N. M. A. Musayeib, H. Hussain and I. Bin Ware, *et al.*, Chemometric Analysis Based on GC-MS Chemical Profiles of Three *Stachys* Species from Uzbekistan and Their Biological Activity, *Plants*, 2022, **11**(9), 1215.
- 219 J. Maree, G. Kamatou, S. Gibbons, A. Viljoen and S. Van Vuuren, The application of GC-MS combined with chemometrics for the identification of antimicrobial compounds from selected commercial essential oils, *Chemom. Intell. Lab. Syst.*, 2014, **130**, 172–181.
- 220 M. Lackner, A. Z. Salem, M. Z. Salem, A. A. Mohamed, J. L. Ponce-Covarrubias and S. Selim, HPLC and GC-MS analyses of phytochemicals from *Ficus carica* leaf extract and essential oil along with their antimicrobial properties, *J. Agric. Food Res.*, 2025, **19**, 101687.

